Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:mercury dibromide
go back to main search page
Accession:CHEBI:49639 term browser browse the term
Definition:A mercury coordination entity composed of mercury and bromine with the formula HgBr2.
Synonyms:exact_synonym: mercury(2+) bromide;   mercury(II) bromide
 related_synonym: DIBROMOMERCURY;   Formula=Br2Hg;   HgBr2;   InChI=1S/2BrH.Hg/h2*1H;/q;;+2/p-2;   InChIKey=NGYIMTKLQULBOO-UHFFFAOYSA-L;   SMILES=Br[Hg]Br;   mercuric bromide;   mercury bromide
 alt_id: CHEBI:33212;   CHEBI:49638
 xref: CAS:7789-47-1;   Gmelin:277818
 xref_mesh: MESH:C042720
 xref: PDBeChem:HG2;   PMID:15074688;   Reaxys:8127939;   Wikipedia:Mercury(II)_bromide



show annotations for term's descendants           Sort by:
 
mercury dibromide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A1BG alpha-1-B glycoprotein decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of A1BG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of A1BG mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:58,345,183...58,353,492
Ensembl chr19:58,345,178...58,353,492
JBrowse link
G ABCB6 ATP binding cassette subfamily B member 6 (Langereis blood group) increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ABCB6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCB6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:219,209,772...219,218,958
Ensembl chr 2:219,209,772...219,218,994
JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ABCC4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCC4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
JBrowse link
G ABCG2 ATP binding cassette subfamily G member 2 (Junior blood group) increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ABCG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
JBrowse link
G ABHD14A abhydrolase domain containing 14A decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ABHD14A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:51,975,064...51,981,196
Ensembl chr 3:51,971,426...51,981,196
JBrowse link
G ABHD3 abhydrolase domain containing 3, phospholipase increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ABHD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABHD3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:21,650,901...21,704,774
Ensembl chr18:21,650,901...21,704,780
JBrowse link
G AC013271.1 novel transcript decreases expression EXP mercuric bromide results in decreased expression of LIMS3-LOC440895 mRNA CTD PMID:26272509 NCBI chr 2:109,898,432...109,968,574
Ensembl chr 2:109,898,432...109,968,557
JBrowse link
G ACP3 acid phosphatase 3 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA CTD PMID:27188386 NCBI chr 3:132,317,407...132,368,302
Ensembl chr 3:132,317,369...132,368,298
JBrowse link
G ACSL1 acyl-CoA synthetase long chain family member 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA CTD PMID:27188386 NCBI chr 4:184,755,595...184,826,594
Ensembl chr 4:184,755,595...184,826,818
JBrowse link
G ACTG2 actin gamma 2, smooth muscle multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTG2 mRNA CTD PMID:27188386 NCBI chr 2:73,893,008...73,919,865
Ensembl chr 2:73,892,314...73,919,865
JBrowse link
G ACTN3 actinin alpha 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ACTN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTN3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:66,546,395...66,563,334
Ensembl chr11:66,546,395...66,563,334
JBrowse link
G ADAM28 ADAM metallopeptidase domain 28 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA CTD PMID:27188386 NCBI chr 8:24,294,069...24,359,014
Ensembl chr 8:24,294,069...24,359,014
JBrowse link
G ADAM9 ADAM metallopeptidase domain 9 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ADAM9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:38,996,973...39,105,261
Ensembl chr 8:38,996,754...39,105,445
JBrowse link
G ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ADAMTS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr21:26,835,755...26,845,409
Ensembl chr21:26,835,755...26,845,409
JBrowse link
G ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif 12 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ADAMTS12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS12 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:33,523,535...33,891,990
Ensembl chr 5:33,523,535...33,892,019
JBrowse link
G ADAMTS2 ADAM metallopeptidase with thrombospondin type 1 motif 2 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS2 mRNA CTD PMID:27188386 NCBI chr 5:179,110,853...179,345,461
Ensembl chr 5:179,110,853...179,345,461
JBrowse link
G ADAMTS20 ADAM metallopeptidase with thrombospondin type 1 motif 20 decreases expression EXP mercuric bromide results in decreased expression of ADAMTS20 mRNA CTD PMID:26272509 NCBI chr12:43,352,763...43,552,203
Ensembl chr12:43,353,866...43,552,203
JBrowse link
G ADCY2 adenylate cyclase 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ADCY2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCY2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:7,396,138...7,830,081
Ensembl chr 5:7,396,138...7,830,081
JBrowse link
G ADCYAP1R1 ADCYAP receptor type I decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ADCYAP1R1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCYAP1R1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:31,052,308...31,111,474
Ensembl chr 7:31,052,308...31,111,479
JBrowse link
G ADGRG2 adhesion G protein-coupled receptor G2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ADGRG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:18,989,307...19,122,956
Ensembl chr  X:18,989,307...19,122,637
JBrowse link
G ADGRG6 adhesion G protein-coupled receptor G6 multiple interactions
increases expression
EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA
mercuric bromide results in increased expression of ADGRG6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:142,302,007...142,446,261
Ensembl chr 6:142,301,854...142,446,266
JBrowse link
G ADM adrenomedullin multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADM mRNA CTD PMID:27188386 NCBI chr11:10,305,073...10,307,397
Ensembl chr11:10,305,073...10,307,397
JBrowse link
G AFAP1L2 actin filament associated protein 1 like 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of AFAP1L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFAP1L2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:114,280,725...114,405,175
Ensembl chr10:114,294,824...114,404,756
JBrowse link
G AFDN-DT AFDN divergent transcript decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of AFDN-DT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:167,823,890...167,826,796
Ensembl chr 6:167,822,103...167,826,833
JBrowse link
G AFP alpha fetoprotein multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFP mRNA CTD PMID:27188386 NCBI chr 4:73,436,221...73,456,174
Ensembl chr 4:73,431,138...73,456,174
JBrowse link
G AGTR1 angiotensin II receptor type 1 increases expression EXP mercuric bromide results in increased expression of AGTR1 mRNA CTD PMID:27188386 NCBI chr 3:148,697,903...148,743,003
Ensembl chr 3:148,697,784...148,743,008
JBrowse link
G AJAP1 adherens junctions associated protein 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of AJAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:4,654,609...4,792,534
Ensembl chr 1:4,654,609...4,792,534
JBrowse link
G AKR1C1 aldo-keto reductase family 1 member C1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of AKR1C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:4,963,415...4,983,283
Ensembl chr10:4,963,253...4,983,283
JBrowse link
G AKR1C2 aldo-keto reductase family 1 member C2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of AKR1C2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:4,987,775...5,018,000
Ensembl chr10:4,987,775...5,018,031
JBrowse link
G AKR1C3 aldo-keto reductase family 1 member C3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of AKR1C3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686
JBrowse link
G ALCAM activated leukocyte cell adhesion molecule increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ALCAM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:105,366,909...105,576,900
Ensembl chr 3:105,366,909...105,576,900
JBrowse link
G ALDH1A3 aldehyde dehydrogenase 1 family member A3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ALDH1A3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:100,879,831...100,916,626
Ensembl chr15:100,877,714...100,916,626
JBrowse link
G ALDH1L2 aldehyde dehydrogenase 1 family member L2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ALDH1L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:105,019,790...105,084,458
Ensembl chr12:105,019,784...105,107,643
JBrowse link
G ALDH3B2 aldehyde dehydrogenase 3 family member B2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ALDH3B2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH3B2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:67,662,155...67,681,252
Ensembl chr11:67,662,155...67,681,224
JBrowse link
G ALKAL2 ALK and LTK ligand 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ALKAL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:279,558...288,091
Ensembl chr 2:279,558...288,851
JBrowse link
G ALPK2 alpha kinase 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ALPK2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALPK2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:58,481,247...58,629,091
Ensembl chr18:58,481,247...58,629,091
JBrowse link
G AMBP alpha-1-microglobulin/bikunin precursor increases expression
multiple interactions
EXP mercuric bromide results in increased expression of AMBP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMBP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:114,060,127...114,078,300
Ensembl chr 9:114,060,127...114,078,328
JBrowse link
G AMER2 APC membrane recruitment protein 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of AMER2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:25,161,679...25,172,288
Ensembl chr13:25,161,679...25,172,288
JBrowse link
G AMIGO2 adhesion molecule with Ig like domain 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of AMIGO2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:47,075,707...47,079,959
Ensembl chr12:47,075,707...47,079,959
JBrowse link
G ANK1 ankyrin 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ANK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:41,653,225...41,896,741
Ensembl chr 8:41,653,220...41,896,762
JBrowse link
G ANKRD1 ankyrin repeat domain 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ANKRD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:90,912,096...90,921,087
Ensembl chr10:90,912,096...90,921,087
JBrowse link
G ANKRD33B ankyrin repeat domain 33B increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ANKRD33B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD33B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:10,564,070...10,657,816
Ensembl chr 5:10,564,070...10,657,816
JBrowse link
G ANKRD36B ankyrin repeat domain 36B increases expression EXP mercuric bromide results in increased expression of ANKRD36B mRNA CTD PMID:26272509 NCBI chr 2:97,492,663...97,589,877
Ensembl chr 2:97,492,663...97,589,877
JBrowse link
G ANTXR1 ANTXR cell adhesion molecule 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ANTXR1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:69,013,144...69,249,327
Ensembl chr 2:69,013,176...69,249,327
JBrowse link
G ANXA1 annexin A1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ANXA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:73,151,865...73,170,393
Ensembl chr 9:73,151,865...73,170,393
JBrowse link
G ANXA2 annexin A2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ANXA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:60,347,151...60,397,986
Ensembl chr15:60,347,134...60,402,883
JBrowse link
G ANXA2P2 annexin A2 pseudogene 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ANXA2P2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:33,624,225...33,625,534
Ensembl chr 9:33,624,274...33,625,293
JBrowse link
G ANXA2P3 annexin A2 pseudogene 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ANXA2P3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:64,825,528...64,826,877
Ensembl chr10:64,825,572...64,826,579
JBrowse link
G ANXA3 annexin A3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ANXA3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:78,551,770...78,610,447
Ensembl chr 4:78,551,747...78,610,451
JBrowse link
G ANXA4 annexin A4 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ANXA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:69,643,808...69,827,112
Ensembl chr 2:69,644,425...69,827,112
JBrowse link
G ANXA9 annexin A9 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA CTD PMID:27188386 NCBI chr 1:150,977,306...150,995,634
Ensembl chr 1:150,982,249...150,995,634
JBrowse link
G AOX1 aldehyde oxidase 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of AOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:200,586,014...200,682,241
Ensembl chr 2:200,586,014...200,677,064
JBrowse link
G APBA2 amyloid beta precursor protein binding family A member 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of APBA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APBA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:28,885,974...29,118,315
Ensembl chr15:28,884,483...29,118,315
JBrowse link
G APCDD1 APC down-regulated 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of APCDD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APCDD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:10,454,635...10,489,949
Ensembl chr18:10,454,635...10,489,949
JBrowse link
G APOA1 apolipoprotein A1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of APOA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622
JBrowse link
G APOA2 apolipoprotein A2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of APOA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:161,222,292...161,223,628
Ensembl chr 1:161,222,292...161,223,631
JBrowse link
G ARAP2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ARAP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of ARAP2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:36,005,404...36,244,784
Ensembl chr 4:35,948,221...36,244,514
JBrowse link
G ARHGAP18 Rho GTPase activating protein 18 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ARHGAP18 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:129,576,132...129,710,177
Ensembl chr 6:129,576,132...129,710,177
JBrowse link
G ARHGDIB Rho GDP dissociation inhibitor beta multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGDIB mRNA CTD PMID:27188386 NCBI chr12:14,942,015...14,961,601
Ensembl chr12:14,942,031...14,961,728
JBrowse link
G ARHGEF25 Rho guanine nucleotide exchange factor 25 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ARHGEF25 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF25 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:57,610,116...57,617,245
Ensembl chr12:57,610,180...57,617,245
JBrowse link
G ARHGEF9 Cdc42 guanine nucleotide exchange factor 9 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ARHGEF9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:63,634,967...63,785,214
Ensembl chr  X:63,634,967...63,809,274
JBrowse link
G ARID5B AT-rich interaction domain 5B increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ARID5B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:61,901,699...62,096,944
Ensembl chr10:61,901,684...62,096,944
JBrowse link
G ARL9 ADP ribosylation factor like GTPase 9 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ARL9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:56,505,209...56,524,453
Ensembl chr 4:56,505,209...56,524,959
JBrowse link
G ARRB1 arrestin beta 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ARRB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:75,260,122...75,351,661
Ensembl chr11:75,260,122...75,351,705
JBrowse link
G ARRDC2 arrestin domain containing 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ARRDC2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARRDC2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:18,001,124...18,014,102
Ensembl chr19:18,001,132...18,014,102
JBrowse link
G ARX aristaless related homeobox decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ARX mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:25,003,694...25,015,965
Ensembl chr  X:25,003,694...25,016,420
JBrowse link
G ASCC3 activating signal cointegrator 1 complex subunit 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ASCC3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCC3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:100,508,194...100,881,329
Ensembl chr 6:100,508,194...100,881,372
JBrowse link
G ASF1A anti-silencing function 1A histone chaperone increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ASF1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASF1A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:118,894,152...118,909,171
Ensembl chr 6:118,894,152...118,909,171
JBrowse link
G ASIC1 acid sensing ion channel subunit 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ASIC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:50,057,596...50,083,622
Ensembl chr12:50,057,548...50,083,611
JBrowse link
G ASNS asparagine synthetase (glutamine-hydrolyzing) increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ASNS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:97,851,677...97,928,441
Ensembl chr 7:97,851,677...97,872,542
JBrowse link
G ASPHD1 aspartate beta-hydroxylase domain containing 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ASPHD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:29,900,363...29,919,864
Ensembl chr16:29,900,375...29,919,864
JBrowse link
G ASTN1 astrotactin 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ASTN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:176,857,321...177,164,712
Ensembl chr 1:176,857,302...177,164,973
JBrowse link
G ATF3 activating transcription factor 3 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF3 mRNA CTD PMID:27188386 NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777
JBrowse link
G ATL3 atlastin GTPase 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ATL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:63,624,087...63,671,974
Ensembl chr11:63,624,087...63,671,921
JBrowse link
G ATP10D ATPase phospholipid transporting 10D (putative) increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ATP10D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP10D mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:47,485,275...47,593,486
Ensembl chr 4:47,485,275...47,593,486
JBrowse link
G ATP2B1-AS1 ATP2B1 antisense RNA 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ATP2B1-AS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP2B1-AS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:89,708,955...89,711,952
Ensembl chr12:89,708,959...89,712,590
JBrowse link
G ATP6V1C1 ATPase H+ transporting V1 subunit C1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ATP6V1C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V1C1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:103,021,083...103,073,051
Ensembl chr 8:103,021,063...103,073,051
JBrowse link
G ATP8A1 ATPase phospholipid transporting 8A1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ATP8A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP8A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:42,408,373...42,657,105
Ensembl chr 4:42,408,373...42,657,121
JBrowse link
G ATP8B1 ATPase phospholipid transporting 8B1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ATP8B1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:57,646,426...57,803,315
Ensembl chr18:57,646,426...57,803,315
JBrowse link
G B9D1 B9 domain containing 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of B9D1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B9D1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:19,334,695...19,377,913
Ensembl chr17:19,334,308...19,378,193
JBrowse link
G BAG2 BAG cochaperone 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BAG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:57,172,326...57,189,833
Ensembl chr 6:57,172,326...57,189,833
JBrowse link
G BAG3 BAG cochaperone 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BAG3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:119,651,380...119,677,819
Ensembl chr10:119,651,380...119,677,819
JBrowse link
G BAMBI BMP and activin membrane bound inhibitor increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BAMBI mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:28,677,521...28,682,932
Ensembl chr10:28,677,510...28,682,932
JBrowse link
G BBS9 Bardet-Biedl syndrome 9 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BBS9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:33,129,285...33,635,767
Ensembl chr 7:33,109,557...33,877,180
JBrowse link
G BCHE butyrylcholinesterase decreases expression EXP mercuric bromide results in decreased expression of BCHE mRNA CTD PMID:26272509 NCBI chr 3:165,772,904...165,837,423
Ensembl chr 3:165,772,904...165,837,462
JBrowse link
G BCL11A BAF chromatin remodeling complex subunit BCL11A increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BCL11A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:60,450,520...60,553,654
Ensembl chr 2:60,450,520...60,554,467
JBrowse link
G BCL2L11 BCL2 like 11 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of BCL2L11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,445
JBrowse link
G BCO1 beta-carotene oxygenase 1 multiple interactions
decreases expression
EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCO1 mRNA
mercuric bromide results in decreased expression of BCO1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:81,238,689...81,291,142
Ensembl chr16:81,238,689...81,291,142
JBrowse link
G BDNF brain derived neurotrophic factor multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BDNF mRNA CTD PMID:27188386 NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
JBrowse link
G BEND4 BEN domain containing 4 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of BEND4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:42,110,853...42,152,655
Ensembl chr 4:42,110,853...42,152,878
JBrowse link
G BEND6 BEN domain containing 6 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BEND6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEND6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:56,955,107...57,027,346
Ensembl chr 6:56,955,107...57,027,346
JBrowse link
G BEST4 bestrophin 4 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of BEST4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:44,781,840...44,792,828
Ensembl chr 1:44,783,585...44,788,170
JBrowse link
G BHLHE40 basic helix-loop-helix family member e40 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BHLHE40 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:4,979,437...4,985,323
Ensembl chr 3:4,979,437...4,985,323
JBrowse link
G BMP4 bone morphogenetic protein 4 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BMP4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:53,949,736...53,956,891
Ensembl chr14:53,949,736...53,958,761
JBrowse link
G BMP5 bone morphogenetic protein 5 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BMP5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:55,753,653...55,875,590
Ensembl chr 6:55,753,653...55,875,590
JBrowse link
G BMP6 bone morphogenetic protein 6 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BMP6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:7,726,099...7,881,728
Ensembl chr 6:7,726,099...7,881,728
JBrowse link
G BMP7 bone morphogenetic protein 7 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BMP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:57,168,753...57,266,641
Ensembl chr20:57,168,753...57,266,641
JBrowse link
G BNC1 basonuclin 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BNC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:83,255,884...83,284,664
Ensembl chr15:83,255,884...83,284,664
JBrowse link
G BNIPL BCL2 interacting protein like multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA CTD PMID:27188386 NCBI chr 1:151,036,586...151,047,720
Ensembl chr 1:151,036,321...151,047,720
JBrowse link
G BOC BOC cell adhesion associated, oncogene regulated decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of BOC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BOC mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:113,210,926...113,287,459
Ensembl chr 3:113,211,003...113,287,459
JBrowse link
G BSPRY B-box and SPRY domain containing multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA CTD PMID:27188386 NCBI chr 9:113,349,541...113,371,222
Ensembl chr 9:113,349,541...113,371,233
JBrowse link
G BST2 bone marrow stromal cell antigen 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of BST2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BST2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:17,402,939...17,405,630
Ensembl chr19:17,402,939...17,405,630
JBrowse link
G BTG2 BTG anti-proliferation factor 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of BTG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:203,305,519...203,309,602
Ensembl chr 1:203,305,491...203,309,602
JBrowse link
G BTG3 BTG anti-proliferation factor 3 increases expression EXP mercuric bromide results in increased expression of BTG3 mRNA CTD PMID:26272509 NCBI chr21:17,593,653...17,612,901
Ensembl chr21:17,593,653...17,612,945
JBrowse link
G C11orf52 chromosome 11 open reading frame 52 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA CTD PMID:27188386 NCBI chr11:111,918,913...111,926,871
Ensembl chr11:111,918,032...111,926,871
JBrowse link
G C11orf96 chromosome 11 open reading frame 96 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of C11ORF96 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C11ORF96 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:43,942,637...43,943,878
Ensembl chr11:43,942,637...43,943,878
JBrowse link
G C1orf210 chromosome 1 open reading frame 210 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of C1ORF210 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1ORF210 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:43,281,877...43,285,857
Ensembl chr 1:43,281,877...43,285,617
JBrowse link
G C1orf226 chromosome 1 open reading frame 226 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of C1ORF226 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF226 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:162,378,841...162,386,812
Ensembl chr 1:162,378,841...162,386,812
JBrowse link
G C1S complement C1s increases expression
multiple interactions
EXP mercuric bromide results in increased expression of C1S mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1S mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:7,060,718...7,071,032
Ensembl chr12:6,988,259...7,071,032
JBrowse link
G C2orf27A chromosome 2 open reading frame 27A decreases expression EXP mercuric bromide results in decreased expression of C2ORF27A mRNA CTD PMID:26272509 NCBI chr 2:131,682,499...131,767,404
Ensembl chr 2:131,647,990...131,767,404
JBrowse link
G C2orf68 chromosome 2 open reading frame 68 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of C2ORF68 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:85,605,254...85,612,066
Ensembl chr 2:85,605,254...85,612,066
JBrowse link
G C3orf70 chromosome 3 open reading frame 70 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of C3ORF70 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF70 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:185,076,838...185,153,060
Ensembl chr 3:185,076,838...185,153,060
JBrowse link
G C4orf19 chromosome 4 open reading frame 19 increases expression EXP mercuric bromide results in increased expression of C4ORF19 mRNA CTD PMID:26272509 NCBI chr 4:37,453,255...37,593,510
Ensembl chr 4:37,453,925...37,623,495
JBrowse link
G C4orf47 chromosome 4 open reading frame 47 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of C4ORF47 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C4ORF47 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:185,408,434...185,449,826
Ensembl chr 4:185,426,249...185,449,826
JBrowse link
G C6orf141 chromosome 6 open reading frame 141 decreases expression EXP mercuric bromide results in decreased expression of C6ORF141 mRNA CTD PMID:26272509 NCBI chr 6:49,550,668...49,561,916
Ensembl chr 6:49,550,666...49,561,907
JBrowse link
G CA13 carbonic anhydrase 13 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA CTD PMID:27188386 NCBI chr 8:85,245,458...85,284,073
Ensembl chr 8:85,220,587...85,284,073
JBrowse link
G CA4 carbonic anhydrase 4 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:60,149,973...60,179,021
Ensembl chr17:60,149,942...60,170,899
JBrowse link
G CAB39L calcium binding protein 39 like increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CAB39L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAB39L mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:49,308,650...49,444,064
Ensembl chr13:49,308,650...49,444,064
JBrowse link
G CACHD1 cache domain containing 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CACHD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACHD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:64,470,129...64,693,053
Ensembl chr 1:64,470,129...64,693,058
JBrowse link
G CACNB2 calcium voltage-gated channel auxiliary subunit beta 2 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA CTD PMID:27188386 NCBI chr10:18,140,424...18,543,557
Ensembl chr10:18,140,424...18,543,557
JBrowse link
G CADM2 cell adhesion molecule 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CADM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:84,958,989...86,074,429
Ensembl chr 3:84,958,989...86,074,429
JBrowse link
G CALB1 calbindin 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CALB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:90,058,608...90,082,879
Ensembl chr 8:90,058,608...90,095,475
JBrowse link
G CAMK2D calcium/calmodulin dependent protein kinase II delta increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CAMK2D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAMK2D mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:113,451,032...113,761,738
Ensembl chr 4:113,418,054...113,761,927
JBrowse link
G CAMK2N1 calcium/calmodulin dependent protein kinase II inhibitor 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CAMK2N1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:20,482,391...20,486,210
Ensembl chr 1:20,482,391...20,486,210
JBrowse link
G CARS1 cysteinyl-tRNA synthetase 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CARS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:3,000,929...3,057,423
Ensembl chr11:3,000,922...3,057,613
JBrowse link
G CASP3 caspase 3 decreases activity EXP mercuric bromide results in decreased activity of CASP3 protein CTD PMID:26272509 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
JBrowse link
G CASP8 caspase 8 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CASP8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:201,233,443...201,287,711
Ensembl chr 2:201,233,443...201,361,836
JBrowse link
G CAV1 caveolin 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CAV1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:116,525,009...116,561,185
Ensembl chr 7:116,524,994...116,561,179
JBrowse link
G CAV2 caveolin 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CAV2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:116,499,738...116,508,541
Ensembl chr 7:116,287,380...116,508,541
JBrowse link
G CC2D1B coiled-coil and C2 domain containing 1B increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CC2D1B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CC2D1B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:52,350,597...52,366,205
Ensembl chr 1:52,345,723...52,366,205
JBrowse link
G CCAR2 cell cycle and apoptosis regulator 2 decreases expression EXP mercuric bromide results in decreased expression of CCAR2 mRNA CTD PMID:26272509 NCBI chr 8:22,604,757...22,621,514
Ensembl chr 8:22,604,757...22,620,964
JBrowse link
G CCBE1 collagen and calcium binding EGF domains 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CCBE1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCBE1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:59,430,939...59,697,721
Ensembl chr18:59,430,939...59,697,662
JBrowse link
G CCDC102A coiled-coil domain containing 102A decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CCDC102A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC102A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:57,512,181...57,537,016
Ensembl chr16:57,512,181...57,536,571
JBrowse link
G CCDC113 coiled-coil domain containing 113 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CCDC113 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC113 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:58,197,015...58,283,836
Ensembl chr16:58,231,157...58,283,836
JBrowse link
G CCDC136 coiled-coil domain containing 136 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CCDC136 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:128,790,761...128,822,130
Ensembl chr 7:128,790,757...128,822,132
JBrowse link
G CCDC177 coiled-coil domain containing 177 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CCDC177 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:69,569,799...69,574,871
Ensembl chr14:69,569,799...69,574,871
JBrowse link
G CCKBR cholecystokinin B receptor decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CCKBR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:6,259,838...6,272,127
Ensembl chr11:6,259,806...6,272,127
JBrowse link
G CCN1 cellular communication network factor 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CCN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:85,580,761...85,583,950
Ensembl chr 1:85,580,761...85,584,589
JBrowse link
G CCN2 cellular communication network factor 2 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA CTD PMID:27188386 NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
JBrowse link
G CCNG2 cyclin G2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CCNG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:77,157,207...77,170,060
Ensembl chr 4:77,157,207...77,433,388
JBrowse link
G CD40 CD40 molecule decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CD40 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CD40 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:46,118,314...46,129,858
Ensembl chr20:46,118,271...46,129,863
JBrowse link
G CD44 CD44 molecule (Indian blood group) multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA CTD PMID:27188386 NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402
JBrowse link
G CD82 CD82 molecule decreases expression EXP mercuric bromide results in decreased expression of CD82 mRNA CTD PMID:26272509 NCBI chr11:44,564,409...44,620,358
Ensembl chr11:44,564,427...44,620,358
JBrowse link
G CD9 CD9 molecule increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CD9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:6,199,946...6,238,266
Ensembl chr12:6,199,715...6,238,271
JBrowse link
G CDC14B cell division cycle 14B multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC14B mRNA CTD PMID:27188386 NCBI chr 9:96,490,939...96,619,843
Ensembl chr 9:96,490,241...96,619,843
JBrowse link
G CDH1 cadherin 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CDH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
JBrowse link
G CDH10 cadherin 10 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CDH10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:24,487,100...24,644,978
Ensembl chr 5:24,487,100...24,644,978
JBrowse link
G CDH13 cadherin 13 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CDH13 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH13 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:82,626,969...83,800,640
Ensembl chr16:82,626,965...83,800,640
JBrowse link
G CDH3 cadherin 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CDH3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:68,645,310...68,733,771
Ensembl chr16:68,636,189...68,727,468
JBrowse link
G CDH6 cadherin 6 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CDH6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:31,193,686...31,329,146
Ensembl chr 5:31,193,686...31,329,146
JBrowse link
G CDH7 cadherin 7 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CDH7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:65,750,252...65,890,337
Ensembl chr18:65,750,252...65,890,337
JBrowse link
G CDH9 cadherin 9 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CDH9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:26,880,597...27,038,586
Ensembl chr 5:26,880,597...27,121,150
JBrowse link
G CDK19 cyclin dependent kinase 19 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CDK19 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:110,609,978...110,815,855
Ensembl chr 6:110,609,978...110,815,958
JBrowse link
G CDK6 cyclin dependent kinase 6 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CDK6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:92,604,921...92,836,573
Ensembl chr 7:92,604,921...92,836,573
JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CDKN1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN1A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
JBrowse link
G CDKN2A cyclin dependent kinase inhibitor 2A increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CDKN2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:21,967,752...21,995,324
Ensembl chr 9:21,967,752...21,995,301
JBrowse link
G CDS1 CDP-diacylglycerol synthase 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CDS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:84,583,127...84,651,334
Ensembl chr 4:84,583,127...84,651,334
JBrowse link
G CEBPB CCAAT enhancer binding protein beta increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CEBPB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:50,190,583...50,192,690
Ensembl chr20:50,190,830...50,192,668
JBrowse link
G CEBPD CCAAT enhancer binding protein delta multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA CTD PMID:27188386 NCBI chr 8:47,736,913...47,738,164
Ensembl chr 8:47,736,913...47,738,164
JBrowse link
G CELF5 CUGBP Elav-like family member 5 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CELF5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:3,224,661...3,297,076
Ensembl chr19:3,224,661...3,297,076
JBrowse link
G CEP85L centrosomal protein 85 like increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CEP85L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:118,460,772...118,710,089
Ensembl chr 6:118,460,772...118,710,075
JBrowse link
G CFAP300 cilia and flagella associated protein 300 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CFAP300 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP300 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:102,047,437...102,084,554
Ensembl chr11:102,047,437...102,084,554
JBrowse link
G CFAP91 cilia and flagella associated protein 91 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CFAP91 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:119,703,022...119,767,102
Ensembl chr 3:119,703,022...119,767,102
JBrowse link
G CFTR CF transmembrane conductance regulator increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CFTR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFTR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971
JBrowse link
G CHAC1 ChaC glutathione specific gamma-glutamylcyclotransferase 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC1 mRNA CTD PMID:27188386 NCBI chr15:40,953,471...40,956,512
Ensembl chr15:40,952,962...40,956,512
JBrowse link
G CHKA choline kinase alpha increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CHKA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHKA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:68,052,859...68,121,388
Ensembl chr11:68,052,859...68,121,444
JBrowse link
G CHMP4C charged multivesicular body protein 4C increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CHMP4C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHMP4C mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:81,732,448...81,759,515
Ensembl chr 8:81,732,448...81,759,515
JBrowse link
G CHODL chondrolectin increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CHODL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr21:17,917,340...18,267,370
Ensembl chr21:17,901,263...18,267,373
JBrowse link
G CHORDC1 cysteine and histidine rich domain containing 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHORDC1 mRNA CTD PMID:27188386 NCBI chr11:90,200,429...90,223,049
Ensembl chr11:90,200,429...90,223,077
JBrowse link
G CHRDL1 chordin like 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CHRDL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:110,673,856...110,795,817
Ensembl chr  X:110,673,856...110,795,819
JBrowse link
G CLDN11 claudin 11 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CLDN11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN11 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:170,418,868...170,434,691
Ensembl chr 3:170,418,868...170,454,733
JBrowse link
G CLDN18 claudin 18 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN18 mRNA CTD PMID:27188386 NCBI chr 3:137,998,816...138,033,649
Ensembl chr 3:137,998,735...138,033,655
JBrowse link
G CLDN4 claudin 4 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CLDN4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:73,830,996...73,832,690
Ensembl chr 7:73,799,542...73,832,690
JBrowse link
G CLDN7 claudin 7 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CLDN7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:7,259,903...7,263,213
Ensembl chr17:7,259,903...7,263,983
JBrowse link
G CLEC18A C-type lectin domain family 18 member A decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CLEC18A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLEC18A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:69,943,519...69,966,623
Ensembl chr16:69,950,705...69,964,452
JBrowse link
G CLN8 CLN8 transmembrane ER and ERGIC protein increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CLN8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLN8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:1,753,059...1,786,570
Ensembl chr 8:1,755,778...1,801,711
JBrowse link
G CNFN cornifelin decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CNFN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNFN mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:42,387,019...42,390,297
Ensembl chr19:42,387,019...42,390,297
JBrowse link
G CNKSR2 connector enhancer of kinase suppressor of Ras 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CNKSR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:21,374,418...21,654,689
Ensembl chr  X:21,372,801...21,654,695
JBrowse link
G CNOT4 CCR4-NOT transcription complex subunit 4 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CNOT4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:135,361,795...135,510,102
Ensembl chr 7:135,361,795...135,510,127
JBrowse link
G CNTN2 contactin 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CNTN2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:205,042,949...205,078,289
Ensembl chr 1:205,042,937...205,078,289
JBrowse link
G CNTNAP3 contactin associated protein family member 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CNTNAP3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:39,064,710...39,288,167
Ensembl chr 9:39,064,710...39,288,315
JBrowse link
G CNTNAP3P2 CNTNAP3 pseudogene 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CNTNAP3P2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3P2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:67,059,460...67,297,156
Ensembl chr 9:67,059,560...67,293,468
JBrowse link
G COA1 cytochrome c oxidase assembly factor 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COA1 mRNA CTD PMID:27188386 NCBI chr 7:43,608,457...43,729,523
Ensembl chr 7:43,608,456...43,729,717
JBrowse link
G COL11A1 collagen type XI alpha 1 chain increases expression
multiple interactions
EXP mercuric bromide results in increased expression of COL11A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL11A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:102,876,473...103,108,522
Ensembl chr 1:102,876,467...103,108,872
JBrowse link
G COL12A1 collagen type XII alpha 1 chain increases expression
multiple interactions
EXP mercuric bromide results in increased expression of COL12A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL12A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:75,084,326...75,206,053
Ensembl chr 6:75,084,326...75,206,267
JBrowse link
G COL1A1 collagen type I alpha 1 chain increases expression
multiple interactions
EXP mercuric bromide results in increased expression of COL1A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
JBrowse link
G COL1A2 collagen type I alpha 2 chain increases expression
multiple interactions
EXP mercuric bromide results in increased expression of COL1A2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227
JBrowse link
G COL3A1 collagen type III alpha 1 chain multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL3A1 mRNA CTD PMID:27188386 NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746
JBrowse link
G COL6A3 collagen type VI alpha 3 chain multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA CTD PMID:27188386 NCBI chr 2:237,324,018...237,414,164
Ensembl chr 2:237,324,003...237,414,328
JBrowse link
G COL8A1 collagen type VIII alpha 1 chain multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL8A1 mRNA CTD PMID:27188386 NCBI chr 3:99,638,594...99,799,217
Ensembl chr 3:99,638,475...99,799,226
JBrowse link
G COLGALT2 collagen beta(1-O)galactosyltransferase 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of COLGALT2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:183,929,662...184,037,728
Ensembl chr 1:183,929,854...184,037,729
JBrowse link
G COPS8 COP9 signalosome subunit 8 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of COPS8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COPS8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:237,085,889...237,100,474
Ensembl chr 2:237,085,882...237,100,474
JBrowse link
G CPE carboxypeptidase E increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CPE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:165,379,008...165,498,547
Ensembl chr 4:165,361,194...165,498,547
JBrowse link
G CPEB2 cytoplasmic polyadenylation element binding protein 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CPEB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:15,002,481...15,070,151
Ensembl chr 4:15,002,481...15,070,153
JBrowse link
G CPT1A carnitine palmitoyltransferase 1A increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CPT1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPT1A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410
JBrowse link
G CPXM2 carboxypeptidase X, M14 family member 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CPXM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:123,745,639...123,944,104
Ensembl chr10:123,706,207...123,940,267
JBrowse link
G CREG1 cellular repressor of E1A stimulated genes 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CREG1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CREG1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:167,541,013...167,553,762
Ensembl chr 1:167,529,117...167,553,805
JBrowse link
G CRIM1 cysteine rich transmembrane BMP regulator 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CRIM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIM1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:36,355,778...36,551,135
Ensembl chr 2:36,355,778...36,551,135
JBrowse link
G CRYBA4 crystallin beta A4 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CRYBA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr22:26,590,220...26,630,669
Ensembl chr22:26,621,963...26,630,669
JBrowse link
G CSF2RA colony stimulating factor 2 receptor subunit alpha increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CSF2RA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:1,268,814...1,325,218
NCBI chr  Y:1,268,814...1,325,218
Ensembl chr  X:1,268,800...1,310,381
JBrowse link
G CSPG5 chondroitin sulfate proteoglycan 5 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CSPG5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:47,562,238...47,580,240
Ensembl chr 3:47,562,238...47,580,792
JBrowse link
G CSRP1 cysteine and glycine rich protein 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSRP1 mRNA CTD PMID:27188386 NCBI chr 1:201,483,530...201,507,123
Ensembl chr 1:201,483,530...201,509,456
JBrowse link
G CST1 cystatin SN multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CST1 mRNA CTD PMID:27188386 NCBI chr20:23,747,562...23,750,935
Ensembl chr20:23,747,562...23,751,268
JBrowse link
G CST4 cystatin S multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CST4 mRNA CTD PMID:27188386 NCBI chr20:23,685,640...23,689,038
Ensembl chr20:23,685,640...23,689,038
JBrowse link
G CTDSP1 CTD small phosphatase 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CTDSP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:218,396,351...218,405,941
Ensembl chr 2:218,398,256...218,405,941
JBrowse link
G CTH cystathionine gamma-lyase increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CTH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTH mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:70,411,268...70,439,851
Ensembl chr 1:70,411,218...70,439,851
JBrowse link
G CTHRC1 collagen triple helix repeat containing 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CTHRC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:103,371,538...103,382,989
Ensembl chr 8:103,371,538...103,382,989
JBrowse link
G CTNND2 catenin delta 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CTNND2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:10,971,836...11,904,446
Ensembl chr 5:10,971,836...11,904,446
JBrowse link
G CTSV cathepsin V increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CTSV mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSV mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:97,029,677...97,039,643
Ensembl chr 9:97,029,677...97,156,556
JBrowse link
G CUL3 cullin 3 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA CTD PMID:27188386 NCBI chr 2:224,470,150...224,585,363
Ensembl chr 2:224,470,150...224,585,397
JBrowse link
G CUTALP cutA divalent cation tolerance like, pseudogene multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUTALP mRNA CTD PMID:27188386 NCBI chr 9:120,843,075...120,854,373
Ensembl chr 9:120,824,828...120,854,385
JBrowse link
G CXCL14 C-X-C motif chemokine ligand 14 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CXCL14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:135,570,679...135,578,991
Ensembl chr 5:135,570,679...135,579,279
JBrowse link
G CXCR4 C-X-C motif chemokine receptor 4 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of CXCR4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:136,114,349...136,118,149
Ensembl chr 2:136,114,349...136,119,177
JBrowse link
G CYB5A cytochrome b5 type A increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CYB5A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYB5A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:74,250,846...74,291,963
Ensembl chr18:74,250,846...74,291,973
JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CYP1A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
JBrowse link
G CYP1B1 cytochrome P450 family 1 subfamily B member 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CYP1B1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
JBrowse link
G CYTH3 cytohesin 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of CYTH3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYTH3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:6,161,779...6,272,624
Ensembl chr 7:6,161,776...6,272,644
JBrowse link
G DAB1 DAB adaptor protein 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DAB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:56,994,778...58,546,726
Ensembl chr 1:56,994,778...58,546,734
JBrowse link
G DCLK2 doublecortin like kinase 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DCLK2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:150,078,445...150,257,438
Ensembl chr 4:150,078,445...150,257,438
JBrowse link
G DCX doublecortin decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DCX mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCX mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:111,293,779...111,412,192
Ensembl chr  X:111,293,779...111,412,429
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDIT3 mRNA CTD PMID:27188386 NCBI chr12:57,516,588...57,521,698
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DDR2 discoidin domain receptor tyrosine kinase 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DDR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDR2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:162,630,863...162,787,405
Ensembl chr 1:162,631,373...162,787,405
JBrowse link
G DENND1B DENN domain containing 1B decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DENND1B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:197,504,748...197,782,150
Ensembl chr 1:197,504,748...197,775,696
JBrowse link
G DGKI diacylglycerol kinase iota decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DGKI mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:137,381,037...137,846,974
Ensembl chr 7:137,381,037...137,847,092
JBrowse link
G DHRS11 dehydrogenase/reductase 11 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DHRS11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHRS11 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:36,591,879...36,600,804
Ensembl chr17:36,591,879...36,600,804
JBrowse link
G DHX15 DEAH-box helicase 15 decreases expression EXP mercuric bromide results in decreased expression of DHX15 mRNA CTD PMID:26272509 NCBI chr 4:24,527,475...24,584,554
Ensembl chr 4:24,517,441...24,584,554
JBrowse link
G DICER1-AS1 DICER1 antisense RNA 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DICER1-AS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DICER1-AS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:95,157,688...95,179,933
Ensembl chr14:95,157,645...95,181,475
JBrowse link
G DIPK1C divergent protein kinase domain 1C decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DIPK1C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:74,434,775...74,464,648
Ensembl chr18:74,434,775...74,457,944
JBrowse link
G DLC1 DLC1 Rho GTPase activating protein increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DLC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:13,083,361...13,604,620
Ensembl chr 8:13,083,361...13,604,610
JBrowse link
G DLL1 delta like canonical Notch ligand 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DLL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:170,282,206...170,291,078
Ensembl chr 6:170,282,206...170,306,565
JBrowse link
G DLX3 distal-less homeobox 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DLX3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:49,990,005...49,995,224
Ensembl chr17:49,990,005...49,995,224
JBrowse link
G DLX5 distal-less homeobox 5 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DLX5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:97,020,396...97,024,831
Ensembl chr 7:97,020,396...97,024,950
JBrowse link
G DLX6 distal-less homeobox 6 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DLX6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:97,005,553...97,011,040
Ensembl chr 7:97,005,553...97,011,040
JBrowse link
G DNAJB1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJB1 mRNA CTD PMID:27188386 NCBI chr19:14,514,769...14,560,391
Ensembl chr19:14,514,769...14,560,391
JBrowse link
G DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DNAJC6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJC6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:65,264,749...65,415,871
Ensembl chr 1:65,248,219...65,415,871
JBrowse link
G DOCK6 dedicator of cytokinesis 6 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DOCK6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:11,199,295...11,262,524
Ensembl chr19:11,199,295...11,262,524
JBrowse link
G DOCK7 dedicator of cytokinesis 7 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DOCK7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:62,454,726...62,688,386
Ensembl chr 1:62,454,298...62,688,386
JBrowse link
G DOCK8 dedicator of cytokinesis 8 decreases expression EXP mercuric bromide results in decreased expression of DOCK8 mRNA CTD PMID:26272509 NCBI chr 9:211,257...465,255
Ensembl chr 9:214,854...465,259
JBrowse link
G DOCK9 dedicator of cytokinesis 9 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DOCK9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:98,793,429...99,088,619
Ensembl chr13:98,793,429...99,086,625
JBrowse link
G DQX1 DEAQ-box RNA dependent ATPase 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DQX1 mRNA CTD PMID:27188386 NCBI chr 2:74,518,131...74,526,231
Ensembl chr 2:74,518,131...74,526,281
JBrowse link
G DRD4 dopamine receptor D4 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DRD4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DRD4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:637,269...640,706
Ensembl chr11:637,269...640,706
JBrowse link
G DSC3 desmocollin 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DSC3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:30,989,365...31,042,742
Ensembl chr18:30,989,365...31,042,815
JBrowse link
G DSP desmoplakin increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DSP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:7,541,671...7,586,714
Ensembl chr 6:7,541,617...7,586,714
JBrowse link
G DSTYK dual serine/threonine and tyrosine protein kinase decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of DSTYK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DSTYK mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:205,142,505...205,211,702
Ensembl chr 1:205,142,505...205,211,702
JBrowse link
G DTNA dystrobrevin alpha increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DTNA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DTNA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:34,493,312...34,891,844
Ensembl chr18:34,493,291...34,891,844
JBrowse link
G DUBR DPPA2 upstream binding RNA increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DUBR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUBR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:107,240,692...107,326,964
Ensembl chr 3:107,220,744...107,348,464
JBrowse link
G DUSP1 dual specificity phosphatase 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP1 mRNA CTD PMID:27188386 NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195
JBrowse link
G DUSP10 dual specificity phosphatase 10 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA CTD PMID:27188386 NCBI chr 1:221,701,424...221,742,089
Ensembl chr 1:221,701,424...221,742,089
JBrowse link
G DUSP14 dual specificity phosphatase 14 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DUSP14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP14 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:37,488,566...37,513,498
Ensembl chr17:37,489,891...37,513,501
JBrowse link
G DUSP2 dual specificity phosphatase 2 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP2 mRNA CTD PMID:27188386 NCBI chr 2:96,143,169...96,145,440
Ensembl chr 2:96,143,169...96,145,440
JBrowse link
G DUSP5 dual specificity phosphatase 5 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of DUSP5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:110,497,907...110,511,533
Ensembl chr10:110,497,907...110,511,533
JBrowse link
G DUSP8 dual specificity phosphatase 8 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP8 mRNA CTD PMID:27188386 NCBI chr11:1,554,051...1,572,848
Ensembl chr11:1,554,051...1,572,271
JBrowse link
G EAF2 ELL associated factor 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of EAF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:121,835,209...121,886,526
Ensembl chr 3:121,835,183...121,886,526
JBrowse link
G EBF1 EBF transcription factor 1 decreases expression EXP mercuric bromide results in decreased expression of EBF1 mRNA CTD PMID:26272509 NCBI chr 5:158,695,920...159,099,916
Ensembl chr 5:158,695,916...159,099,916
JBrowse link
G EDN1 endothelin 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA CTD PMID:27188386 NCBI chr 6:12,256,484...12,297,194
Ensembl chr 6:12,290,361...12,297,194
JBrowse link
G EDNRB endothelin receptor type B increases expression EXP mercuric bromide results in increased expression of EDNRB mRNA CTD PMID:26272509 NCBI chr13:77,895,481...77,975,527
Ensembl chr13:77,895,481...77,975,529
JBrowse link
G EEF1AKMT2 EEF1A lysine methyltransferase 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of EEF1AKMT2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:124,757,834...124,791,887
Ensembl chr10:124,748,149...124,791,887
JBrowse link
G EFHC2 EF-hand domain containing 2 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFHC2 mRNA CTD PMID:27188386 NCBI chr  X:44,147,872...44,343,672
Ensembl chr  X:44,147,872...44,343,672
JBrowse link
G EFNA1 ephrin A1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA CTD PMID:27188386 NCBI chr 1:155,127,876...155,134,899
Ensembl chr 1:155,127,876...155,134,899
JBrowse link
G EFNA2 ephrin A2 decreases expression EXP mercuric bromide results in decreased expression of EFNA2 mRNA CTD PMID:26272509 NCBI chr19:1,284,227...1,301,431
Ensembl chr19:1,285,873...1,301,431
JBrowse link
G EGF epidermal growth factor increases expression
multiple interactions
EXP mercuric bromide results in increased expression of EGF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGF mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
JBrowse link
G EGFL7 EGF like domain multiple 7 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of EGFL7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFL7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:136,658,856...136,672,678
Ensembl chr 9:136,658,856...136,672,678
JBrowse link
G EID3 EP300 interacting inhibitor of differentiation 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of EID3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:104,303,739...104,305,205
Ensembl chr12:104,303,739...104,305,205
JBrowse link
G EIF4E3 eukaryotic translation initiation factor 4E family member 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of EIF4E3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:71,659,363...71,754,773
Ensembl chr 3:71,675,414...71,754,773
JBrowse link
G ELF3 E74 like ETS transcription factor 3 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA CTD PMID:27188386 NCBI chr 1:202,010,587...202,017,183
Ensembl chr 1:202,007,945...202,017,183
JBrowse link
G ELF4 E74 like ETS transcription factor 4 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ELF4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:130,063,955...130,111,927
Ensembl chr  X:130,063,955...130,110,716
JBrowse link
G ELF5 E74 like ETS transcription factor 5 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ELF5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:34,478,791...34,513,794
Ensembl chr11:34,478,791...34,525,193
JBrowse link
G ELK3 ETS transcription factor ELK3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ELK3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:96,194,375...96,269,824
Ensembl chr12:96,194,375...96,269,824
JBrowse link
G ELMOD1 ELMO domain containing 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:107,591,147...107,666,779
Ensembl chr11:107,591,091...107,666,779
JBrowse link
G EMP1 epithelial membrane protein 1 increases expression EXP mercuric bromide results in increased expression of EMP1 mRNA CTD PMID:26272509 NCBI chr12:13,196,726...13,219,941
Ensembl chr12:13,196,723...13,219,941
JBrowse link
G ENSA endosulfine alpha increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ENSA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:150,621,246...150,629,612
Ensembl chr 1:150,600,851...150,629,612
JBrowse link
G EOGT EGF domain specific O-linked N-acetylglucosamine transferase increases expression
multiple interactions
EXP mercuric bromide results in increased expression of EOGT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:68,975,225...69,013,684
Ensembl chr 3:68,975,217...69,013,684
JBrowse link
G EPAS1 endothelial PAS domain protein 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of EPAS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:46,297,407...46,386,697
Ensembl chr 2:46,293,667...46,386,697
JBrowse link
G EPB41L3 erythrocyte membrane protein band 4.1 like 3 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA CTD PMID:27188386 NCBI chr18:5,392,386...5,630,663
Ensembl chr18:5,392,381...5,630,700
JBrowse link
G EPB41L5 erythrocyte membrane protein band 4.1 like 5 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of EPB41L5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:120,013,077...120,179,119
Ensembl chr 2:120,013,077...120,179,119
JBrowse link
G EPCAM epithelial cell adhesion molecule increases expression
multiple interactions
EXP mercuric bromide results in increased expression of EPCAM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:47,369,311...47,387,020
Ensembl chr 2:47,345,158...47,387,601
JBrowse link
G EPDR1 ependymin related 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of EPDR1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPDR1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:37,920,640...37,951,936
Ensembl chr 7:37,920,640...37,951,936
JBrowse link
G EPHA2 EPH receptor A2 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA2 mRNA CTD PMID:27188386 NCBI chr 1:16,124,337...16,156,069
Ensembl chr 1:16,124,337...16,156,069
JBrowse link
G EPHB1 EPH receptor B1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of EPHB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:134,795,260...135,260,467
Ensembl chr 3:134,795,260...135,260,467
JBrowse link
G EPHB2 EPH receptor B2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:22,710,838...22,921,500
Ensembl chr 1:22,710,839...22,921,500
JBrowse link
G EPN3 epsin 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of EPN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:50,532,735...50,543,750
Ensembl chr17:50,532,682...50,543,750
JBrowse link
G EPS8L2 EPS8 like 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of EPS8L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:706,231...727,727
Ensembl chr11:694,438...727,727
JBrowse link
G EPSTI1 epithelial stromal interaction 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of EPSTI1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:42,886,388...42,992,241
Ensembl chr13:42,886,388...42,992,271
JBrowse link
G ERAP1 endoplasmic reticulum aminopeptidase 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ERAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:96,760,813...96,935,854
Ensembl chr 5:96,760,810...96,808,100
JBrowse link
G ERICH1 glutamate rich 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ERICH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERICH1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:614,746...731,224
Ensembl chr 8:614,746...738,106
JBrowse link
G ERICH5 glutamate rich 5 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ERICH5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERICH5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:98,064,568...98,093,609
Ensembl chr 8:98,064,522...98,093,610
JBrowse link
G ERO1B endoplasmic reticulum oxidoreductase 1 beta multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA CTD PMID:27188386 NCBI chr 1:236,215,101...236,281,958
Ensembl chr 1:236,214,681...236,282,019
JBrowse link
G ERP27 endoplasmic reticulum protein 27 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ERP27 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:14,914,039...14,938,537
Ensembl chr12:14,914,039...14,938,537
JBrowse link
G ESRP1 epithelial splicing regulatory protein 1 increases expression EXP mercuric bromide results in increased expression of ESRP1 mRNA CTD PMID:26272509 NCBI chr 8:94,641,174...94,707,466
Ensembl chr 8:94,641,074...94,707,466
JBrowse link
G ESRP2 epithelial splicing regulatory protein 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ESRP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:68,229,033...68,236,127
Ensembl chr16:68,229,033...68,238,102
JBrowse link
G ETNK1 ethanolamine kinase 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ETNK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:22,625,171...22,690,665
Ensembl chr12:22,625,075...22,690,665
JBrowse link
G ETS1 ETS proto-oncogene 1, transcription factor increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ETS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:128,458,765...128,587,558
Ensembl chr11:128,458,761...128,587,558
JBrowse link
G EVC2 EvC ciliary complex subunit 2 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EVC2 mRNA CTD PMID:27188386 NCBI chr 4:5,529,011...5,709,548
Ensembl chr 4:5,542,772...5,709,548
JBrowse link
G EXD3 exonuclease 3'-5' domain containing 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of EXD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXD3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:137,306,896...137,423,162
Ensembl chr 9:137,306,896...137,423,211
JBrowse link
G F2RL2 coagulation factor II thrombin receptor like 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of F2RL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:76,615,482...76,623,403
Ensembl chr 5:76,615,482...76,623,413
JBrowse link
G F3 coagulation factor III, tissue factor increases expression
multiple interactions
EXP mercuric bromide results in increased expression of F3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
JBrowse link
G F5 coagulation factor V increases expression
multiple interactions
EXP mercuric bromide results in increased expression of F5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:169,511,951...169,586,481
Ensembl chr 1:169,511,951...169,586,588
JBrowse link
G FAM110C family with sequence similarity 110 member C increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FAM110C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110C mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:38,814...46,505
Ensembl chr 2:38,814...46,870
JBrowse link
G FAM124A family with sequence similarity 124 member A decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of FAM124A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:51,222,398...51,284,239
Ensembl chr13:51,222,334...51,284,239
JBrowse link
G FAM13C family with sequence similarity 13 member C increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FAM13C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:59,246,129...59,363,181
Ensembl chr10:59,246,130...59,363,181
JBrowse link
G FAM149A family with sequence similarity 149 member A decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of FAM149A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:186,104,704...186,175,337
Ensembl chr 4:186,104,419...186,175,337
JBrowse link
G FAM162B family with sequence similarity 162 member B multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA CTD PMID:27188386 NCBI chr 6:116,752,197...116,765,719
Ensembl chr 6:116,752,197...116,765,719
JBrowse link
G FAM169A family with sequence similarity 169 member A increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FAM169A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM169A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:74,777,574...74,866,966
Ensembl chr 5:74,777,574...74,866,966
JBrowse link
G FAM222A family with sequence similarity 222 member A decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of FAM222A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:109,713,825...109,770,495
Ensembl chr12:109,713,825...109,770,495
JBrowse link
G FAM241A family with sequence similarity 241 member A multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA CTD PMID:27188386 NCBI chr 4:112,145,454...112,195,256
Ensembl chr 4:112,145,454...112,195,256
JBrowse link
G FAM89A family with sequence similarity 89 member A increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FAM89A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:231,018,958...231,040,254
Ensembl chr 1:231,018,958...231,040,254
JBrowse link
G FAS Fas cell surface death receptor increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FAS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAS mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
JBrowse link
G FBLIM1 filamin binding LIM protein 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLIM1 mRNA CTD PMID:27188386 NCBI chr 1:15,756,638...15,786,589
Ensembl chr 1:15,756,607...15,786,594
JBrowse link
G FBXO9 F-box protein 9 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of FBXO9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:53,057,802...53,100,873
Ensembl chr 6:53,051,991...53,100,873
JBrowse link
G FECH ferrochelatase increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FECH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FECH mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:57,544,377...57,586,702
Ensembl chr18:57,544,377...57,586,732
JBrowse link
G FEZ1 fasciculation and elongation protein zeta 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of FEZ1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:125,442,881...125,496,265
Ensembl chr11:125,442,881...125,592,568
JBrowse link
G FEZF2 FEZ family zinc finger 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of FEZF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:62,369,681...62,373,550
Ensembl chr 3:62,369,681...62,374,324
JBrowse link
G FGB fibrinogen beta chain increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FGB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:154,562,980...154,572,807
Ensembl chr 4:154,563,011...154,572,807
JBrowse link
G FGF9 fibroblast growth factor 9 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA CTD PMID:27188386 NCBI chr13:21,671,073...21,704,498
Ensembl chr13:21,671,073...21,704,498
JBrowse link
G FGFR2 fibroblast growth factor receptor 2 decreases expression EXP mercuric bromide results in decreased expression of FGFR2 mRNA CTD PMID:26272509 NCBI chr10:121,478,330...121,598,458
Ensembl chr10:121,478,332...121,598,458
JBrowse link
G FHOD3 formin homology 2 domain containing 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of FHOD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:36,297,713...36,780,220
Ensembl chr18:36,297,713...36,780,220
JBrowse link
G FJX1 four-jointed box kinase 1 decreases expression EXP mercuric bromide results in decreased expression of FJX1 mRNA CTD PMID:26272509 NCBI chr11:35,618,460...35,620,865
Ensembl chr11:35,618,460...35,620,865
JBrowse link
G FKBP5 FKBP prolyl isomerase 5 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of FKBP5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FKBP5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
JBrowse link
G FLI1 Fli-1 proto-oncogene, ETS transcription factor multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLI1 mRNA CTD PMID:27188386 NCBI chr11:128,685,351...128,813,267
Ensembl chr11:128,686,535...128,813,267
JBrowse link
G FLNB filamin B increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FLNB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLNB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:58,008,422...58,172,251
Ensembl chr 3:58,008,398...58,172,251
JBrowse link
G FLNC filamin C increases expression EXP mercuric bromide results in increased expression of FLNC mRNA CTD PMID:26272509 NCBI chr 7:128,830,406...128,859,272
Ensembl chr 7:128,830,406...128,859,274
JBrowse link
G FLT1 fms related receptor tyrosine kinase 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FLT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:28,300,346...28,495,128
Ensembl chr13:28,300,346...28,495,145
JBrowse link
G FN1 fibronectin 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073
JBrowse link
G FNDC4 fibronectin type III domain containing 4 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of FNDC4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:27,491,883...27,495,200
Ensembl chr 2:27,491,883...27,495,200
JBrowse link
G FNDC5 fibronectin type III domain containing 5 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of FNDC5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:32,862,268...32,872,484
Ensembl chr 1:32,862,268...32,872,482
JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FOSL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
JBrowse link
G FOSL2 FOS like 2, AP-1 transcription factor subunit increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FOSL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:28,392,858...28,417,317
Ensembl chr 2:28,392,448...28,417,317
JBrowse link
G FOXC1 forkhead box C1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FOXC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:1,609,915...1,613,897
Ensembl chr 6:1,609,915...1,613,897
JBrowse link
G FOXC2 forkhead box C2 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA CTD PMID:27188386 NCBI chr16:86,566,829...86,569,728
Ensembl chr16:86,566,829...86,569,728
JBrowse link
G FOXL2 forkhead box L2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FOXL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:138,944,224...138,947,137
Ensembl chr 3:138,944,224...138,947,137
JBrowse link
G FREM1 FRAS1 related extracellular matrix 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FREM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:14,737,152...14,910,995
Ensembl chr 9:14,737,152...14,910,995
JBrowse link
G FRMD3 FERM domain containing 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of FRMD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:83,242,992...83,585,794
Ensembl chr 9:83,242,990...83,538,546
JBrowse link
G FRZB frizzled related protein multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA CTD PMID:27188386 NCBI chr 2:182,833,275...182,866,637
Ensembl chr 2:182,833,275...182,866,637
JBrowse link
G FTH1 ferritin heavy chain 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FTH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTH1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634
JBrowse link
G FTL ferritin light chain increases expression
multiple interactions
EXP mercuric bromide results in increased expression of FTL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:48,965,309...48,966,879
Ensembl chr19:48,965,309...48,966,879
JBrowse link
G FTX FTX transcript, XIST regulator increases expression EXP mercuric bromide results in increased expression of FTX mRNA CTD PMID:26272509 NCBI chr  X:74,028,136...74,293,574
Ensembl chr  X:73,940,435...74,293,574
JBrowse link
G FZD10 frizzled class receptor 10 decreases expression EXP mercuric bromide results in decreased expression of FZD10 mRNA CTD PMID:26272509 NCBI chr12:130,162,464...130,165,740
Ensembl chr12:130,162,459...130,165,740
JBrowse link
G GABARAPL1 GABA type A receptor associated protein like 1 increases expression EXP mercuric bromide results in increased expression of GABARAPL1 mRNA CTD PMID:26272509 NCBI chr12:10,212,877...10,223,128
Ensembl chr12:10,212,458...10,223,128
JBrowse link
G GABRA5 gamma-aminobutyric acid type A receptor subunit alpha5 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GABRA5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:26,866,719...26,949,208
Ensembl chr15:26,866,911...26,949,208
JBrowse link
G GABRB2 gamma-aminobutyric acid type A receptor subunit beta2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GABRB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:161,288,436...161,548,404
Ensembl chr 5:161,288,429...161,549,044
JBrowse link
G GABRB3 gamma-aminobutyric acid type A receptor subunit beta3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GABRB3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:26,543,552...26,773,763
Ensembl chr15:26,543,546...26,939,539
JBrowse link
G GABRP gamma-aminobutyric acid type A receptor subunit pi increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GABRP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:170,782,720...170,814,047
Ensembl chr 5:170,763,350...170,814,047
JBrowse link
G GADD45A growth arrest and DNA damage inducible alpha increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GADD45A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334
JBrowse link
G GADD45B growth arrest and DNA damage inducible beta multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA CTD PMID:27188386 NCBI chr19:2,476,127...2,478,257
Ensembl chr19:2,476,122...2,478,259
JBrowse link
G GAL galanin and GMAP prepropeptide decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GAL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:68,684,544...68,691,175
Ensembl chr11:68,683,779...68,691,175
JBrowse link
G GALNT10 polypeptide N-acetylgalactosaminyltransferase 10 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GALNT10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:154,190,733...154,420,984
Ensembl chr 5:154,190,730...154,420,984
JBrowse link
G GALNT14 polypeptide N-acetylgalactosaminyltransferase 14 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GALNT14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT14 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:30,886,782...31,138,440
Ensembl chr 2:30,910,467...31,155,202
JBrowse link
G GALNT3 polypeptide N-acetylgalactosaminyltransferase 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GALNT3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:165,747,588...165,794,692
Ensembl chr 2:165,747,588...165,794,659
JBrowse link
G GALP galanin like peptide decreases expression EXP mercuric bromide results in decreased expression of GALP mRNA CTD PMID:26272509 NCBI chr19:56,176,008...56,185,775
Ensembl chr19:56,176,008...56,185,775
JBrowse link
G GAS1 growth arrest specific 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GAS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:86,944,362...86,947,506
Ensembl chr 9:86,944,362...86,947,506
JBrowse link
G GAS2L1 growth arrest specific 2 like 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GAS2L1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS2L1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr22:29,306,650...29,312,787
Ensembl chr22:29,306,618...29,312,787
JBrowse link
G GASK1B golgi associated kinase 1B multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GASK1B mRNA CTD PMID:27188386 NCBI chr 4:158,124,474...158,173,025
Ensembl chr 4:158,124,474...158,173,318
JBrowse link
G GATA2 GATA binding protein 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GATA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:128,479,422...128,493,201
Ensembl chr 3:128,479,427...128,493,201
JBrowse link
G GATA3 GATA binding protein 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GATA3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:8,045,333...8,075,198
Ensembl chr10:8,045,378...8,075,198
JBrowse link
G GATA6 GATA binding protein 6 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GATA6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:22,169,589...22,202,528
Ensembl chr18:22,169,589...22,202,528
JBrowse link
G GCLC glutamate-cysteine ligase catalytic subunit increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GCLC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLC mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
JBrowse link
G GCLM glutamate-cysteine ligase modifier subunit increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GCLM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLM mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456
JBrowse link
G GCNA germ cell nuclear acidic peptidase increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GCNA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCNA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:71,578,437...71,613,583
Ensembl chr  X:71,578,437...71,613,583
JBrowse link
G GCNT1 glucosaminyl (N-acetyl) transferase 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GCNT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:76,441,666...76,507,416
Ensembl chr 9:76,419,850...76,651,203
JBrowse link
G GDAP1L1 ganglioside induced differentiation associated protein 1 like 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GDAP1L1 mRNA CTD PMID:27188386 NCBI chr20:44,247,099...44,280,947
Ensembl chr20:44,247,099...44,280,947
JBrowse link
G GDF15 growth differentiation factor 15 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GDF15 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF15 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:18,386,158...18,389,176
Ensembl chr19:18,374,731...18,389,176
JBrowse link
G GJB2 gap junction protein beta 2 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA CTD PMID:27188386 NCBI chr13:20,187,470...20,192,938
Ensembl chr13:20,187,463...20,192,938
JBrowse link
G GLIPR1 GLI pathogenesis related 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLIPR1 mRNA CTD PMID:27188386 NCBI chr12:75,480,755...75,503,863
Ensembl chr12:75,480,753...75,503,863
JBrowse link
G GLIS3 GLIS family zinc finger 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GLIS3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:3,824,127...4,490,465
Ensembl chr 9:3,824,127...4,348,392
JBrowse link
G GLRX2 glutaredoxin 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GLRX2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:193,096,465...193,106,114
Ensembl chr 1:193,090,866...193,106,114
JBrowse link
G GLS glutaminase increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GLS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:190,880,821...190,965,552
Ensembl chr 2:190,880,821...190,965,552
JBrowse link
G GNA14 G protein subunit alpha 14 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GNA14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNA14 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:77,423,079...77,648,322
Ensembl chr 9:77,423,079...77,648,322
JBrowse link
G GNAS GNAS complex locus increases expression EXP mercuric bromide results in increased expression of GNAS mRNA CTD PMID:26272509 NCBI chr20:58,839,748...58,911,192
Ensembl chr20:58,839,718...58,911,192
JBrowse link
G GNAS-AS1 GNAS antisense RNA 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GNAS-AS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNAS-AS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:58,818,918...58,850,903
Ensembl chr20:58,818,918...58,850,903
JBrowse link
G GNE glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GNE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNE mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:36,214,441...36,276,978
Ensembl chr 9:36,214,441...36,277,042
JBrowse link
G GNG11 G protein subunit gamma 11 increases expression EXP mercuric bromide results in increased expression of GNG11 mRNA CTD PMID:26272509 NCBI chr 7:93,921,735...93,928,610
Ensembl chr 7:93,921,735...93,928,610
JBrowse link
G GNG8 G protein subunit gamma 8 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GNG8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:46,633,953...46,639,326
Ensembl chr19:46,633,953...46,636,541
JBrowse link
G GPAT3 glycerol-3-phosphate acyltransferase 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GPAT3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPAT3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:83,535,587...83,605,875
Ensembl chr 4:83,535,914...83,605,875
JBrowse link
G GPM6A glycoprotein M6A increases expression EXP mercuric bromide results in increased expression of GPM6A mRNA CTD PMID:26272509 NCBI chr 4:175,632,937...176,002,691
Ensembl chr 4:175,632,934...176,002,664
JBrowse link
G GPM6B glycoprotein M6B decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GPM6B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPM6B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:13,770,939...13,938,638
Ensembl chr  X:13,770,939...13,938,638
JBrowse link
G GPNMB glycoprotein nmb increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GPNMB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPNMB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:23,246,775...23,275,108
Ensembl chr 7:23,235,967...23,275,108
JBrowse link
G GPR153 G protein-coupled receptor 153 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GPR153 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR153 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:6,247,353...6,261,098
Ensembl chr 1:6,247,353...6,261,098
JBrowse link
G GPR27 G protein-coupled receptor 27 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GPR27 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:71,753,855...71,756,496
Ensembl chr 3:71,753,855...71,756,496
JBrowse link
G GPR37 G protein-coupled receptor 37 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GPR37 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:124,743,885...124,765,792
Ensembl chr 7:124,743,885...124,765,792
JBrowse link
G GPR39 G protein-coupled receptor 39 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GPR39 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR39 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:132,416,805...132,646,582
Ensembl chr 2:132,416,805...132,646,582
JBrowse link
G GPR87 G protein-coupled receptor 87 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GPR87 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR87 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:151,294,086...151,316,820
Ensembl chr 3:151,294,086...151,316,820
JBrowse link
G GPRC5A G protein-coupled receptor class C group 5 member A increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GPRC5A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPRC5A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:12,891,562...12,917,937
Ensembl chr12:12,891,559...12,917,937
JBrowse link
G GPX3 glutathione peroxidase 3 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPX3 mRNA CTD PMID:27188386 NCBI chr 5:151,020,591...151,028,988
Ensembl chr 5:151,020,591...151,028,988
JBrowse link
G GRAMD1C GRAM domain containing 1C decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GRAMD1C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRAMD1C mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:113,828,192...113,947,174
Ensembl chr 3:113,828,182...113,947,174
JBrowse link
G GREM1 gremlin 1, DAN family BMP antagonist increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GREM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:32,718,004...32,745,106
Ensembl chr15:32,718,004...32,745,106
JBrowse link
G GRHL1 grainyhead like transcription factor 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA CTD PMID:27188386 NCBI chr 2:9,951,693...10,002,277
Ensembl chr 2:9,951,693...10,002,277
JBrowse link
G GRHL2 grainyhead like transcription factor 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GRHL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:101,492,439...101,681,200
Ensembl chr 8:101,492,439...101,669,726
JBrowse link
G GRHL3 grainyhead like transcription factor 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GRHL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:24,319,357...24,364,482
Ensembl chr 1:24,199,558...24,364,482
JBrowse link
G GRIA3 glutamate ionotropic receptor AMPA type subunit 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GRIA3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:123,184,278...123,490,915
Ensembl chr  X:123,184,153...123,490,915
JBrowse link
G GRIN2A glutamate ionotropic receptor NMDA type subunit 2A decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GRIN2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:9,753,404...10,182,908
Ensembl chr16:9,753,404...10,182,928
JBrowse link
G GSR glutathione-disulfide reductase increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GSR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
JBrowse link
G GSTM2 glutathione S-transferase mu 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GSTM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSTM2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
JBrowse link
G GSTP1 glutathione S-transferase pi 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GSTP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSTP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
JBrowse link
G GUCA1A guanylate cyclase activator 1A decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of GUCA1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCA1A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:42,173,364...42,180,056
Ensembl chr 6:42,173,364...42,181,338
JBrowse link
G GULP1 GULP PTB domain containing engulfment adaptor 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of GULP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GULP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:188,291,874...188,595,926
Ensembl chr 2:188,291,669...188,595,931
JBrowse link
G GXYLT2 glucoside xylosyltransferase 2 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GXYLT2 mRNA CTD PMID:27188386 NCBI chr 3:72,888,046...72,976,915
Ensembl chr 3:72,888,046...72,998,138
JBrowse link
G H1-3 H1.3 linker histone, cluster member decreases expression EXP mercuric bromide results in decreased expression of H1-3 mRNA CTD PMID:26272509 NCBI chr 6:26,234,212...26,234,987
Ensembl chr 6:26,234,212...26,234,987
JBrowse link
G H2AC6 H2A clustered histone 6 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of H2AC6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:26,124,172...26,124,690
Ensembl chr 6:26,124,145...26,139,116
JBrowse link
G H2BC21 H2B clustered histone 21 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of H2BC21 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC21 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:149,884,459...149,886,682
Ensembl chr 1:149,884,459...149,886,682
JBrowse link
G H2BC5 H2B clustered histone 5 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of H2BC5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:26,158,121...26,171,349
Ensembl chr 6:26,158,122...26,171,349
JBrowse link
G HACD1 3-hydroxyacyl-CoA dehydratase 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of HACD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:17,589,032...17,617,374
Ensembl chr10:17,589,032...17,617,374
JBrowse link
G HAND1 heart and neural crest derivatives expressed 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA CTD PMID:27188386 NCBI chr 5:154,474,972...154,478,227
Ensembl chr 5:154,474,972...154,478,227
JBrowse link
G HAPLN1 hyaluronan and proteoglycan link protein 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of HAPLN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:83,637,805...83,720,855
Ensembl chr 5:83,637,805...83,720,855
JBrowse link
G HCG11 HLA complex group 11 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of HCG11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HCG11 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:26,521,706...26,527,393
Ensembl chr 6:26,521,709...26,527,404
JBrowse link
G HDLBP high density lipoprotein binding protein decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of HDLBP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HDLBP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:241,227,291...241,315,672
Ensembl chr 2:241,227,264...241,317,061
JBrowse link
G HERC2P2 HERC2 pseudogene 2 increases expression EXP mercuric bromide results in increased expression of HERC2P2 mRNA CTD PMID:26272509 NCBI chr15:22,494,837...22,590,831
Ensembl chr15:22,495,570...22,590,820
JBrowse link
G HERC5 HECT and RLD domain containing E3 ubiquitin protein ligase 5 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of HERC5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:88,457,119...88,506,163
Ensembl chr 4:88,457,119...88,506,163
JBrowse link
G HERPUD1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERPUD1 mRNA CTD PMID:27188386 NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864
JBrowse link
G HES5 hes family bHLH transcription factor 5 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of HES5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:2,528,745...2,530,263
Ensembl chr 1:2,528,745...2,530,263
JBrowse link
G HEXA hexosaminidase subunit alpha increases expression
multiple interactions
EXP mercuric bromide results in increased expression of HEXA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEXA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:72,340,924...72,376,014
Ensembl chr15:72,340,924...72,376,420
JBrowse link
G HGSNAT heparan-alpha-glucosaminide N-acetyltransferase decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of HGSNAT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HGSNAT mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:43,140,464...43,202,855
Ensembl chr 8:43,140,464...43,202,855
JBrowse link
G HIF3A hypoxia inducible factor 3 subunit alpha multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIF3A mRNA CTD PMID:27188386 NCBI chr19:46,297,042...46,343,433
Ensembl chr19:46,297,042...46,343,433
JBrowse link
G HIVEP1 HIVEP zinc finger 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIVEP1 mRNA CTD PMID:27188386 NCBI chr 6:12,007,693...12,212,048
Ensembl chr 6:12,008,762...12,164,999
JBrowse link
G HLA-DMA major histocompatibility complex, class II, DM alpha multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMA mRNA CTD PMID:27188386 NCBI chr 6:32,948,618...32,953,097
Ensembl chr 6:32,948,613...32,969,094
JBrowse link
G HLA-DMB major histocompatibility complex, class II, DM beta decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of HLA-DMB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:32,934,636...32,941,028
Ensembl chr 6:32,934,629...32,941,028
JBrowse link
G HLA-DOA major histocompatibility complex, class II, DO alpha decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of HLA-DOA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DOA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:33,004,182...33,009,591
Ensembl chr 6:33,004,182...33,009,591
JBrowse link
G HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of HMGCS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:43,287,470...43,313,412
Ensembl chr 5:43,287,470...43,313,512
JBrowse link
G HMOX1 heme oxygenase 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of HMOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
JBrowse link
G HNMT histamine N-methyltransferase increases expression
multiple interactions
EXP mercuric bromide results in increased expression of HNMT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:137,964,473...138,016,364
Ensembl chr 2:137,964,020...138,016,364
JBrowse link
G HNRNPR heterogeneous nuclear ribonucleoprotein R decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of HNRNPR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:23,304,688...23,344,284
Ensembl chr 1:23,303,771...23,344,336
JBrowse link
G HPGD 15-hydroxyprostaglandin dehydrogenase increases expression
multiple interactions
EXP mercuric bromide results in increased expression of HPGD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:174,490,175...174,522,893
Ensembl chr 4:174,490,175...174,523,154
JBrowse link
G HRH3 histamine receptor H3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of HRH3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRH3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:62,214,960...62,220,278
Ensembl chr20:62,214,960...62,220,278
JBrowse link
G HRK harakiri, BCL2 interacting protein increases expression
multiple interactions
EXP mercuric bromide results in increased expression of HRK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:116,856,144...116,881,441
Ensembl chr12:116,856,144...116,881,441
JBrowse link
G HS3ST1 heparan sulfate-glucosamine 3-sulfotransferase 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of HS3ST1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HS3ST1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:11,393,150...11,434,327
Ensembl chr 4:11,393,150...11,429,564
JBrowse link
G HS3ST3A1 heparan sulfate-glucosamine 3-sulfotransferase 3A1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of HS3ST3A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:13,494,032...13,601,929
Ensembl chr17:13,494,032...13,601,929
JBrowse link
G HS3ST3B1 heparan sulfate-glucosamine 3-sulfotransferase 3B1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of HS3ST3B1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:14,301,081...14,349,404
Ensembl chr17:14,301,081...14,349,404
JBrowse link
G HSD17B8 hydroxysteroid 17-beta dehydrogenase 8 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of HSD17B8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSD17B8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:33,204,655...33,206,831
Ensembl chr 6:33,204,655...33,206,831
JBrowse link
G HSPA4L heat shock protein family A (Hsp70) member 4 like increases expression
multiple interactions
EXP mercuric bromide results in increased expression of HSPA4L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:127,781,796...127,840,733
Ensembl chr 4:127,781,821...127,840,733
JBrowse link
G HSPB8 heat shock protein family B (small) member 8 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPB8 mRNA CTD PMID:27188386 NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
JBrowse link
G HSPH1 heat shock protein family H (Hsp110) member 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPH1 mRNA CTD PMID:27188386 NCBI chr13:31,134,973...31,162,388
Ensembl chr13:31,134,973...31,162,388
JBrowse link
G HTATIP2 HIV-1 Tat interactive protein 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of HTATIP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HTATIP2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:20,363,714...20,383,782
Ensembl chr11:20,363,685...20,383,782
JBrowse link
G HTRA1 HtrA serine peptidase 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of HTRA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTRA1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:122,461,553...122,514,907
Ensembl chr10:122,458,551...122,514,907
JBrowse link
G ID1 inhibitor of DNA binding 1, HLH protein increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ID1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:31,605,289...31,606,510
Ensembl chr20:31,605,283...31,606,515
JBrowse link
G IDH3A isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha increases expression
multiple interactions
EXP mercuric bromide results in increased expression of IDH3A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:78,149,362...78,171,945
Ensembl chr15:78,131,498...78,171,945
JBrowse link
G IDS iduronate 2-sulfatase increases expression
multiple interactions
EXP mercuric bromide results in increased expression of IDS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDS mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:149,476,988...149,505,306
Ensembl chr  X:149,476,988...149,521,096
JBrowse link
G IER3 immediate early response 3 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA CTD PMID:27188386 NCBI chr 6:30,743,199...30,744,547
Ensembl chr 6:30,743,199...30,744,548
JBrowse link
G IFI16 interferon gamma inducible protein 16 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA CTD PMID:27188386 NCBI chr 1:158,999,976...159,055,151
Ensembl chr 1:158,999,968...159,055,155
JBrowse link
G IFRD1 interferon related developmental regulator 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFRD1 mRNA CTD PMID:27188386 NCBI chr 7:112,423,174...112,477,203
Ensembl chr 7:112,422,887...112,481,017
JBrowse link
G IFT57 intraflagellar transport 57 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of IFT57 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT57 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:108,160,812...108,222,424
Ensembl chr 3:108,160,812...108,222,435
JBrowse link
G IGFBP3 insulin like growth factor binding protein 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of IGFBP3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:45,912,245...45,921,272
Ensembl chr 7:45,912,245...45,921,874
JBrowse link
G IGFBP5 insulin like growth factor binding protein 5 decreases expression EXP mercuric bromide results in decreased expression of IGFBP5 mRNA CTD PMID:26272509 NCBI chr 2:216,672,105...216,695,549
Ensembl chr 2:216,672,105...216,695,549
JBrowse link
G IGFBP6 insulin like growth factor binding protein 6 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP6 mRNA CTD PMID:27188386 NCBI chr12:53,097,667...53,102,340
Ensembl chr12:53,097,436...53,102,345
JBrowse link
G IGFBP7 insulin like growth factor binding protein 7 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of IGFBP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:57,030,773...57,110,385
Ensembl chr 4:57,030,773...57,110,385
JBrowse link
G IGSF21 immunoglobin superfamily member 21 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of IGSF21 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:18,107,798...18,378,483
Ensembl chr 1:18,107,798...18,378,483
JBrowse link
G IL13RA1 interleukin 13 receptor subunit alpha 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of IL13RA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL13RA1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:118,727,606...118,805,228
Ensembl chr  X:118,727,133...118,794,535
JBrowse link
G IL1RAP interleukin 1 receptor accessory protein multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAP mRNA CTD PMID:27188386 NCBI chr 3:190,514,085...190,659,750
Ensembl chr 3:190,514,051...190,659,750
JBrowse link
G IL6 interleukin 6 increases expression EXP mercuric bromide results in increased expression of IL6 mRNA CTD PMID:26272509 NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
JBrowse link
G IL6R interleukin 6 receptor increases expression
multiple interactions
EXP mercuric bromide results in increased expression of IL6R mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL6R mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:154,405,343...154,469,450
Ensembl chr 1:154,405,193...154,469,450
JBrowse link
G INF2 inverted formin 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of INF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:104,689,618...104,722,535
Ensembl chr14:104,681,146...104,722,535
JBrowse link
G INHBE inhibin subunit beta E increases expression
multiple interactions
EXP mercuric bromide results in increased expression of INHBE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:57,455,307...57,458,025
Ensembl chr12:57,452,323...57,459,280
JBrowse link
G INO80D INO80 complex subunit D decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of INO80D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INO80D mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:205,993,721...206,086,174
Ensembl chr 2:205,993,721...206,086,303
JBrowse link
G INPP5D inositol polyphosphate-5-phosphatase D increases expression
multiple interactions
EXP mercuric bromide results in increased expression of INPP5D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:233,060,342...233,207,903
Ensembl chr 2:233,059,967...233,207,903
JBrowse link
G INSIG1 insulin induced gene 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of INSIG1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INSIG1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235
JBrowse link
G IPW imprinted in Prader-Willi syndrome multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPW mRNA CTD PMID:27188386 NCBI chr15:25,116,545...25,122,476 JBrowse link
G IQCE IQ motif containing E decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of IQCE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IQCE mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:2,558,979...2,614,728
Ensembl chr 7:2,558,972...2,614,733
JBrowse link
G IRS1 insulin receptor substrate 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of IRS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:226,731,312...226,799,820
Ensembl chr 2:226,731,312...226,799,820
JBrowse link
G ISL1 ISL LIM homeobox 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA CTD PMID:27188386 NCBI chr 5:51,383,448...51,394,730
Ensembl chr 5:51,383,448...51,394,730
JBrowse link
G ISL2 ISL LIM homeobox 2 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL2 mRNA CTD PMID:27188386 NCBI chr15:76,336,773...76,342,475
Ensembl chr15:76,336,773...76,342,475
JBrowse link
G IST1 IST1 factor associated with ESCRT-III multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IST1 mRNA CTD PMID:27188386 NCBI chr16:71,894,408...71,931,199
Ensembl chr16:71,845,996...71,931,199
JBrowse link
G ITGA4 integrin subunit alpha 4 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of ITGA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGA4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:181,457,205...181,538,940
Ensembl chr 2:181,457,202...181,538,940
JBrowse link
G ITGA8 integrin subunit alpha 8 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ITGA8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:15,513,954...15,719,922
Ensembl chr10:15,513,954...15,719,922
JBrowse link
G ITGB6 integrin subunit beta 6 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ITGB6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGB6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:160,099,671...160,200,272
Ensembl chr 2:160,099,667...160,200,313
JBrowse link
G ITIH5 inter-alpha-trypsin inhibitor heavy chain 5 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ITIH5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:7,559,270...7,666,966
Ensembl chr10:7,559,270...7,666,998
JBrowse link
G ITM2A integral membrane protein 2A increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ITM2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:79,360,384...79,367,334
Ensembl chr  X:79,360,384...79,367,667
JBrowse link
G ITM2B integral membrane protein 2B increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ITM2B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:48,233,206...48,270,357
Ensembl chr13:48,232,612...48,270,357
JBrowse link
G ITPR2 inositol 1,4,5-trisphosphate receptor type 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ITPR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:26,335,352...26,833,194
Ensembl chr12:26,335,352...26,833,194
JBrowse link
G JAM2 junctional adhesion molecule 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of JAM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAM2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr21:25,639,258...25,717,562
Ensembl chr21:25,639,258...25,717,562
JBrowse link
G JAZF1 JAZF zinc finger 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of JAZF1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAZF1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:27,830,577...28,180,795
Ensembl chr 7:27,830,573...28,180,795
JBrowse link
G JPH4 junctophilin 4 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of JPH4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JPH4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:23,568,038...23,578,790
Ensembl chr14:23,568,038...23,578,790
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUN mRNA CTD PMID:27188386 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
JBrowse link
G KAT6A lysine acetyltransferase 6A decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of KAT6A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:41,929,479...42,051,987
Ensembl chr 8:41,929,479...42,051,994
JBrowse link
G KATNBL1 katanin regulatory subunit B1 like 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of KATNBL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KATNBL1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:34,140,674...34,210,096
Ensembl chr15:34,140,674...34,210,096
JBrowse link
G KCNJ12 potassium inwardly rectifying channel subfamily J member 12 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of KCNJ12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ12 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:21,376,357...21,419,870
Ensembl chr17:21,376,357...21,419,870
JBrowse link
G KCNK1 potassium two pore domain channel subfamily K member 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of KCNK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:233,614,106...233,672,514
Ensembl chr 1:233,614,106...233,672,514
JBrowse link
G KCNK10 potassium two pore domain channel subfamily K member 10 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of KCNK10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:88,180,108...88,326,912
Ensembl chr14:88,180,103...88,326,907
JBrowse link
G KCNQ2 potassium voltage-gated channel subfamily Q member 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of KCNQ2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNQ2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:63,400,208...63,472,655
Ensembl chr20:63,400,208...63,472,677
JBrowse link
G KCTD1 potassium channel tetramerization domain containing 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of KCTD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:26,454,910...26,657,473
Ensembl chr18:26,454,910...26,657,401
JBrowse link
G KCTD12 potassium channel tetramerization domain containing 12 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of KCTD12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:76,880,175...76,886,405
Ensembl chr13:76,880,175...76,886,405
JBrowse link
G KEAP1 kelch like ECH associated protein 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of KEAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KEAP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558
JBrowse link
G KIAA1217 KIAA1217 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of KIAA1217 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1217 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:23,694,727...24,547,843
Ensembl chr10:23,694,746...24,547,848
JBrowse link
G KIF1A kinesin family member 1A multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF1A mRNA CTD PMID:27188386 NCBI chr 2:240,713,767...240,821,403
Ensembl chr 2:240,713,761...240,824,293
JBrowse link
G KITLG KIT ligand increases expression
multiple interactions
EXP mercuric bromide results in increased expression of KITLG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:88,492,793...88,580,471
Ensembl chr12:88,492,793...88,580,851
JBrowse link
G KLF11 KLF transcription factor 11 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of KLF11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF11 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:10,043,550...10,054,836
Ensembl chr 2:10,042,849...10,054,836
JBrowse link
G KLF5 KLF transcription factor 5 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of KLF5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:73,054,976...73,077,538
Ensembl chr13:73,054,976...73,077,541
JBrowse link
G KLF6 KLF transcription factor 6 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of KLF6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281
JBrowse link
G KLF9 KLF transcription factor 9 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA CTD PMID:27188386 NCBI chr 9:70,384,604...70,414,657
Ensembl chr 9:70,384,604...70,414,657
JBrowse link
G KLHDC8A kelch domain containing 8A decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of KLHDC8A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:205,336,061...205,357,039
Ensembl chr 1:205,336,061...205,357,090
JBrowse link
G KLHL21 kelch like family member 21 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL21 mRNA CTD PMID:27188386 NCBI chr 1:6,590,724...6,602,869
Ensembl chr 1:6,590,724...6,614,607
JBrowse link
G KLHL4 kelch like family member 4 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL4 mRNA CTD PMID:27188386 NCBI chr  X:87,517,802...87,670,050
Ensembl chr  X:87,517,409...87,670,050
JBrowse link
G KLHL5 kelch like family member 5 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL5 mRNA CTD PMID:27188386 NCBI chr 4:39,044,827...39,143,101
Ensembl chr 4:39,045,039...39,126,857
JBrowse link
G KLK8 kallikrein related peptidase 8 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of KLK8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLK8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:50,996,008...51,001,604
Ensembl chr19:50,996,007...51,002,711
JBrowse link
G KNDC1 kinase non-catalytic C-lobe domain containing 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of KNDC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KNDC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:133,160,219...133,226,412
Ensembl chr10:133,160,219...133,226,412
JBrowse link
G KRAS KRAS proto-oncogene, GTPase decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of KRAS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:25,205,246...25,250,929
Ensembl chr12:25,205,246...25,250,936
JBrowse link
G KRT18 keratin 18 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of KRT18 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:52,948,855...52,952,906
Ensembl chr12:52,948,871...52,952,906
JBrowse link
G KRT8 keratin 8 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of KRT8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:52,897,191...52,949,860
Ensembl chr12:52,897,187...52,949,954
JBrowse link
G LACC1 laccase domain containing 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LACC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:43,879,178...43,893,932
Ensembl chr13:43,879,284...43,893,932
JBrowse link
G LACTB lactamase beta multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA CTD PMID:27188386 NCBI chr15:63,121,861...63,142,061
Ensembl chr15:63,121,833...63,142,061
JBrowse link
G LAMC2 laminin subunit gamma 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LAMC2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:183,186,264...183,258,968
Ensembl chr 1:183,186,238...183,245,127
JBrowse link
G LAMP2 lysosomal associated membrane protein 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LAMP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:120,426,148...120,469,349
Ensembl chr  X:120,426,148...120,469,365
JBrowse link
G LAYN layilin increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LAYN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:111,540,280...111,561,745
Ensembl chr11:111,540,280...111,561,745
JBrowse link
G LGALS3 galectin 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LGALS3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:55,129,252...55,145,430
Ensembl chr14:55,124,110...55,145,423
JBrowse link
G LGALS8 galectin 8 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LGALS8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:236,518,214...236,552,981
Ensembl chr 1:236,518,000...236,552,981
JBrowse link
G LHFPL4 LHFPL tetraspan subfamily member 4 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of LHFPL4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHFPL4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:9,498,361...9,553,822
Ensembl chr 3:9,498,361...9,553,822
JBrowse link
G LHFPL6 LHFPL tetraspan subfamily member 6 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LHFPL6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:39,342,892...39,603,193
Ensembl chr13:39,209,116...39,603,528
JBrowse link
G LHX2 LIM homeobox 2 decreases expression EXP mercuric bromide results in decreased expression of LHX2 mRNA CTD PMID:26272509 NCBI chr 9:124,011,768...124,033,301
Ensembl chr 9:124,001,670...124,033,301
JBrowse link
G LHX4 LIM homeobox 4 increases expression EXP mercuric bromide results in increased expression of LHX4 mRNA CTD PMID:26272509 NCBI chr 1:180,228,375...180,278,984
Ensembl chr 1:180,230,264...180,278,984
JBrowse link
G LHX8 LIM homeobox 8 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA CTD PMID:27188386 NCBI chr 1:75,128,434...75,199,454
Ensembl chr 1:75,128,434...75,161,533
JBrowse link
G LIFR LIF receptor subunit alpha increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LIFR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:38,474,668...38,608,403
Ensembl chr 5:38,474,668...38,608,354
JBrowse link
G LIM2 lens intrinsic membrane protein 2 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA CTD PMID:27188386 NCBI chr19:51,379,909...51,387,974
Ensembl chr19:51,379,909...51,387,974
JBrowse link
G LIMCH1 LIM and calponin homology domains 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIMCH1 mRNA CTD PMID:27188386 NCBI chr 4:41,359,607...41,700,044
Ensembl chr 4:41,359,607...41,700,044
JBrowse link
G LINC-PINT long intergenic non-protein coding RNA, p53 induced transcript increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LINC-PINT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC-PINT mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:130,877,562...131,109,925
Ensembl chr 7:130,791,264...131,110,176
JBrowse link
G LINC00648 long intergenic non-protein coding RNA 648 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of LINC00648 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00648 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:47,764,953...47,795,014
Ensembl chr14:47,764,954...47,795,302
JBrowse link
G LINC01088 long intergenic non-protein coding RNA 1088 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01088 mRNA CTD PMID:27188386 NCBI chr 4:78,971,748...79,308,799
Ensembl chr 4:78,939,485...79,309,673
JBrowse link
G LINC01128 long intergenic non-protein coding RNA 1128 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LINC01128 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01128 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:827,591...859,446
Ensembl chr 1:825,138...859,446
JBrowse link
G LINC01138 long intergenic non-protein coding RNA 1138 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC01138 mRNA CTD PMID:27188386 NCBI chr 1:148,432,959...148,459,920
Ensembl chr 1:148,290,889...148,519,604
JBrowse link
G LINC01405 long intergenic non-protein coding RNA 1405 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01405 mRNA CTD PMID:27188386 NCBI chr12:110,936,602...110,937,448
Ensembl chr12:110,934,590...110,959,093
JBrowse link
G LIX1 limb and CNS expressed 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of LIX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:97,091,867...97,142,611
Ensembl chr 5:97,091,867...97,142,753
JBrowse link
G LMAN1 lectin, mannose binding 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of LMAN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:59,327,823...59,359,265
Ensembl chr18:59,327,823...59,359,265
JBrowse link
G LMNA lamin A/C increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LMNA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMNA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:156,082,573...156,140,081
Ensembl chr 1:156,082,573...156,140,081
JBrowse link
G LMO1 LIM domain only 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of LMO1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:8,224,309...8,268,787
Ensembl chr11:8,224,309...8,268,716
JBrowse link
G LMO3 LIM domain only 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of LMO3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:16,548,372...16,610,174
Ensembl chr12:16,548,372...16,610,594
JBrowse link
G LMO7 LIM domain 7 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LMO7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:75,620,434...75,859,870
Ensembl chr13:75,620,434...75,859,870
JBrowse link
G LNX1 ligand of numb-protein X 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LNX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:53,459,301...53,652,477
Ensembl chr 4:53,459,301...53,701,405
JBrowse link
G LPAR3 lysophosphatidic acid receptor 3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of LPAR3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPAR3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:84,811,602...84,893,206
Ensembl chr 1:84,811,602...84,893,206
JBrowse link
G LPAR6 lysophosphatidic acid receptor 6 increases expression EXP mercuric bromide results in increased expression of LPAR6 mRNA CTD PMID:26272509 NCBI chr13:48,389,571...48,444,669
Ensembl chr13:48,389,567...48,444,704
JBrowse link
G LRP10 LDL receptor related protein 10 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LRP10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRP10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:22,871,740...22,881,713
Ensembl chr14:22,871,740...22,881,713
JBrowse link
G LRRC34 leucine rich repeat containing 34 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of LRRC34 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC34 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:169,793,003...169,812,904
Ensembl chr 3:169,793,003...169,812,986
JBrowse link
G LRRC3B leucine rich repeat containing 3B decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of LRRC3B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:26,622,772...26,710,776
Ensembl chr 3:26,622,772...26,717,537
JBrowse link
G LRRN4 leucine rich repeat neuronal 4 increases expression EXP mercuric bromide results in increased expression of LRRN4 mRNA CTD PMID:26272509 NCBI chr20:6,040,546...6,054,060
Ensembl chr20:6,040,546...6,054,060
JBrowse link
G LSAMP limbic system associated membrane protein decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of LSAMP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSAMP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:115,802,374...116,445,487
Ensembl chr 3:115,802,363...117,139,389
JBrowse link
G LY6K lymphocyte antigen 6 family member K increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LY6K mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY6K mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:142,700,111...142,705,127
Ensembl chr 8:142,700,111...142,705,127
JBrowse link
G LYVE1 lymphatic vessel endothelial hyaluronan receptor 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of LYVE1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYVE1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:10,556,966...10,568,665
Ensembl chr11:10,556,966...10,611,689
JBrowse link
G LZTS1 leucine zipper tumor suppressor 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA CTD PMID:27188386 NCBI chr 8:20,246,165...20,303,963
Ensembl chr 8:20,246,165...20,303,963
JBrowse link
G MAB21L2 mab-21 like 2 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MAB21L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:150,582,151...150,584,693
Ensembl chr 4:150,582,151...150,584,693
JBrowse link
G MACC1 MET transcriptional regulator MACC1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MACC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:20,134,655...20,217,384
Ensembl chr 7:20,134,655...20,217,404
JBrowse link
G MACROH2A1 macroH2A.1 histone decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MACROH2A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:135,334,381...135,399,887
Ensembl chr 5:135,334,381...135,399,914
JBrowse link
G MAFB MAF bZIP transcription factor B multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFB mRNA CTD PMID:27188386 NCBI chr20:40,685,848...40,689,236
Ensembl chr20:40,685,848...40,689,236
JBrowse link
G MAFF MAF bZIP transcription factor F multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFF mRNA CTD PMID:27188386 NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
JBrowse link
G MAFG MAF bZIP transcription factor G increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MAFG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFG mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:81,918,270...81,931,244
Ensembl chr17:81,918,270...81,927,735
JBrowse link
G MAGI2-AS3 MAGI2 antisense RNA 3 increases expression EXP mercuric bromide results in increased expression of MAGI2-AS3 mRNA CTD PMID:26272509 NCBI chr 7:79,452,957...79,471,208
Ensembl chr 7:79,452,877...79,471,208
JBrowse link
G MAL2 mal, T cell differentiation protein 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MAL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:119,208,363...119,245,673
Ensembl chr 8:119,165,034...119,245,673
JBrowse link
G MAN1A1 mannosidase alpha class 1A member 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MAN1A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:119,177,205...119,350,605
Ensembl chr 6:119,177,205...119,349,761
JBrowse link
G MAN1C1 mannosidase alpha class 1C member 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MAN1C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN1C1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:25,616,791...25,784,450
Ensembl chr 1:25,616,791...25,786,206
JBrowse link
G MAP1A microtubule associated protein 1A increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MAP1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:43,510,954...43,531,611
Ensembl chr15:43,510,958...43,531,620
JBrowse link
G MAP2K6 mitogen-activated protein kinase kinase 6 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MAP2K6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
JBrowse link
G MAP3K14 mitogen-activated protein kinase kinase kinase 14 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K14 mRNA CTD PMID:27188386 NCBI chr17:45,263,119...45,317,020
Ensembl chr17:45,263,119...45,317,029
JBrowse link
G MAP3K5 mitogen-activated protein kinase kinase kinase 5 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K5 mRNA CTD PMID:27188386 NCBI chr 6:136,557,046...136,793,091
Ensembl chr 6:136,557,046...136,793,097
JBrowse link
G MAP4 microtubule associated protein 4 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MAP4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:47,850,695...48,088,848
Ensembl chr 3:47,850,690...48,089,272
JBrowse link
G MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 increases expression EXP mercuric bromide results in increased expression of MAP4K4 mRNA CTD PMID:26272509 NCBI chr 2:101,697,707...101,894,690
Ensembl chr 2:101,696,850...101,894,690
JBrowse link
G MAP6 microtubule associated protein 6 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA CTD PMID:27188386 NCBI chr11:75,586,918...75,669,038
Ensembl chr11:75,586,918...75,669,038
JBrowse link
G MAP7 microtubule associated protein 7 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MAP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:136,342,734...136,550,422
Ensembl chr 6:136,342,281...136,550,819
JBrowse link
G MAPK10 mitogen-activated protein kinase 10 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MAPK10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:86,010,405...86,594,074
Ensembl chr 4:85,990,007...86,594,625
JBrowse link
G MARVELD3 MARVEL domain containing 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MARVELD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARVELD3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:71,626,184...71,641,965
Ensembl chr16:71,626,161...71,642,114
JBrowse link
G MAST4 microtubule associated serine/threonine kinase family member 4 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MAST4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAST4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:66,596,393...67,169,593
Ensembl chr 5:66,596,380...67,169,593
JBrowse link
G MBD2 methyl-CpG binding domain protein 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MBD2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBD2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:54,151,606...54,224,669
Ensembl chr18:54,151,606...54,224,669
JBrowse link
G MBNL3 muscleblind like splicing regulator 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MBNL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:132,369,320...132,490,035
Ensembl chr  X:132,369,320...132,489,968
JBrowse link
G MBOAT1 membrane bound O-acyltransferase domain containing 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MBOAT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:20,099,684...20,212,469
Ensembl chr 6:20,099,684...20,212,469
JBrowse link
G MCC MCC regulator of WNT signaling pathway increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MCC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:113,022,106...113,488,453
Ensembl chr 5:113,022,099...113,488,823
JBrowse link
G MCM7 minichromosome maintenance complex component 7 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MCM7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCM7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:100,092,728...100,101,397
Ensembl chr 7:100,092,728...100,101,940
JBrowse link
G MCOLN3 mucolipin TRP cation channel 3 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MCOLN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:85,018,082...85,048,500
Ensembl chr 1:85,018,082...85,048,500
JBrowse link
G MCTP1 multiple C2 and transmembrane domain containing 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MCTP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCTP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:94,703,690...95,285,094
Ensembl chr 5:94,703,690...95,285,094
JBrowse link
G MDM2 MDM2 proto-oncogene increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MDM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:68,808,172...68,850,686
Ensembl chr12:68,808,177...68,845,544
JBrowse link
G ME1 malic enzyme 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of ME1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ME1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:83,210,402...83,431,051
Ensembl chr 6:83,210,402...83,431,051
JBrowse link
G MEGF10 multiple EGF like domains 10 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MEGF10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEGF10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:127,229,300...127,461,222
Ensembl chr 5:127,290,796...127,465,737
JBrowse link
G MEIOB meiosis specific with OB-fold decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MEIOB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIOB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:1,833,986...1,872,164
Ensembl chr16:1,833,986...1,872,178
JBrowse link
G MELTF melanotransferrin decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MELTF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MELTF mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:197,001,740...197,029,817
Ensembl chr 3:196,980,590...197,029,835
JBrowse link
G MEOX1 mesenchyme homeobox 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MEOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:43,640,389...43,661,922
Ensembl chr17:43,640,389...43,661,922
JBrowse link
G METTL7A methyltransferase like 7A increases expression
multiple interactions
EXP mercuric bromide results in increased expression of METTL7A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METTL7A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:50,925,015...50,932,508
Ensembl chr12:50,923,472...50,932,510
JBrowse link
G MFAP3L microfibril associated protein 3 like decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MFAP3L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:169,986,602...170,027,277
Ensembl chr 4:169,986,597...170,033,031
JBrowse link
G MFAP5 microfibril associated protein 5 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MFAP5 mRNA CTD PMID:27188386 NCBI chr12:8,645,943...8,662,826
Ensembl chr12:8,637,346...8,662,888
JBrowse link
G MFNG MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MFNG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr22:37,469,063...37,486,384
Ensembl chr22:37,469,063...37,486,393
JBrowse link
G MGARP mitochondria localized glutamic acid rich protein multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MGARP mRNA CTD PMID:27188386 NCBI chr 4:139,266,165...139,280,225
Ensembl chr 4:139,266,165...139,280,225
JBrowse link
G MIF4GD MIF4G domain containing decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MIF4GD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIF4GD mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:75,266,228...75,271,292
Ensembl chr17:75,266,228...75,271,231
JBrowse link
G MIR124-2HG MIR124-2 host gene multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR124-2HG mRNA CTD PMID:27188386 NCBI chr 8:64,373,218...64,387,504
Ensembl chr 8:64,373,105...64,383,919
JBrowse link
G MIR210HG MIR210 host gene decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MIR210HG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR210HG mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:565,657...568,457
Ensembl chr11:565,657...568,457
JBrowse link
G MIR22HG MIR22 host gene increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MIR22HG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:1,711,504...1,716,272
Ensembl chr17:1,711,447...1,717,174
JBrowse link
G MITF melanocyte inducing transcription factor increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MITF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MITF mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:69,739,464...69,968,332
Ensembl chr 3:69,739,456...69,968,336
JBrowse link
G MMAB metabolism of cobalamin associated B decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MMAB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:109,553,715...109,573,504
Ensembl chr12:109,553,715...109,573,580
JBrowse link
G MMP14 matrix metallopeptidase 14 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MMP14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:22,836,585...22,847,758
Ensembl chr14:22,836,560...22,849,041
JBrowse link
G MMP16 matrix metallopeptidase 16 decreases expression EXP mercuric bromide results in decreased expression of MMP16 mRNA CTD PMID:26272509 NCBI chr 8:88,032,011...88,327,483
Ensembl chr 8:88,032,011...88,328,025
JBrowse link
G MNX1 motor neuron and pancreas homeobox 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MNX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:157,004,854...157,010,663
Ensembl chr 7:156,994,051...157,010,663
JBrowse link
G MPZL2 myelin protein zero like 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MPZL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:118,253,416...118,264,297
Ensembl chr11:118,253,416...118,264,536
JBrowse link
G MRGPRF MAS related GPR family member F multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MRGPRF mRNA CTD PMID:27188386 NCBI chr11:69,004,398...69,013,633
Ensembl chr11:69,004,395...69,013,382
JBrowse link
G MRPL4 mitochondrial ribosomal protein L4 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MRPL4 mRNA CTD PMID:27188386 NCBI chr19:10,251,951...10,260,055
Ensembl chr19:10,251,901...10,260,055
JBrowse link
G MSRB3 methionine sulfoxide reductase B3 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MSRB3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:65,278,683...65,466,907
Ensembl chr12:65,278,643...65,491,430
JBrowse link
G MSX1 msh homeobox 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MSX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:4,859,665...4,863,936
Ensembl chr 4:4,859,665...4,863,936
JBrowse link
G MSX2 msh homeobox 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MSX2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:174,724,582...174,730,896
Ensembl chr 5:174,724,582...174,730,896
JBrowse link
G MT1E metallothionein 1E increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MT1E mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1E mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:56,625,781...56,627,112
Ensembl chr16:56,625,475...56,627,112
JBrowse link
G MT1F metallothionein 1F increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MT1F mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1F mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:56,657,959...56,659,303
Ensembl chr16:56,657,731...56,660,698
JBrowse link
G MT1G metallothionein 1G increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MT1G mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1G mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:56,666,730...56,668,065
Ensembl chr16:56,666,730...56,668,065
JBrowse link
G MT1H metallothionein 1H increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MT1H mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1H mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:56,669,814...56,671,129
Ensembl chr16:56,669,814...56,671,129
JBrowse link
G MT1HL1 metallothionein 1H like 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MT1HL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1HL1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:237,004,103...237,004,441
Ensembl chr 1:237,004,103...237,004,441
JBrowse link
G MT1X metallothionein 1X increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MT1X mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1X mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:56,682,470...56,684,196
Ensembl chr16:56,682,470...56,684,196
JBrowse link
G MT2A metallothionein 2A increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MT2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT2A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497
JBrowse link
G MTSS1 MTSS I-BAR domain containing 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MTSS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTSS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:124,550,784...124,728,473
Ensembl chr 8:124,550,784...124,728,473
JBrowse link
G MUC15 mucin 15, cell surface associated increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MUC15 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:26,559,032...26,572,263
Ensembl chr11:26,559,032...26,572,263
JBrowse link
G MYCL MYCL proto-oncogene, bHLH transcription factor decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MYCL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYCL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:39,895,428...39,901,917
Ensembl chr 1:39,895,426...39,902,256
JBrowse link
G MYCT1 MYC target 1 multiple interactions EXP [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA CTD PMID:27188386 NCBI chr 6:152,697,897...152,747,181
Ensembl chr 6:152,697,897...152,724,569
JBrowse link
G MYLK myosin light chain kinase decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of MYLK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:123,610,049...123,884,332
Ensembl chr 3:123,610,049...123,884,332
JBrowse link
G MYO10 myosin X increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MYO10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:16,661,907...16,936,288
Ensembl chr 5:16,661,907...16,936,288
JBrowse link
G MYO1D myosin ID increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MYO1D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:32,492,522...32,877,124
Ensembl chr17:32,492,522...32,877,177
JBrowse link
G MYOF myoferlin increases expression
multiple interactions
EXP mercuric bromide results in increased expression of MYOF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:93,306,429...93,482,334
Ensembl chr10:93,306,429...93,482,334
JBrowse link
G N4BP2L2 NEDD4 binding protein 2 like 2 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of N4BP2L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP2L2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:32,432,485...32,538,868
Ensembl chr13:32,432,417...32,538,885
JBrowse link
G NABP1 nucleic acid binding protein 1 increases expression
multiple interactions
EXP mercuric bromide results in increased expression of NABP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:191,678,136...191,686,943
Ensembl chr 2:191,678,068...191,741,097
JBrowse link
G NAT1 N-acetyltransferase 1 increases expression EXP mercuric bromide results in increased expression of NAT1 mRNA CTD PMID:26272509 NCBI chr 8:18,170,467...18,223,689
Ensembl chr 8:18,170,477...18,223,689
JBrowse link
G NAV1 neuron navigator 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of NAV1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:201,539,127...201,826,969
Ensembl chr 1:201,539,127...201,826,969
JBrowse link
G NCALD neurocalcin delta decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of NCALD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:101,686,542...102,124,907
Ensembl chr 8:101,686,542...102,124,907
JBrowse link
G NCAM1 neural cell adhesion molecule 1 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of NCAM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAM1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:112,961,420...113,278,436
Ensembl chr11:112,961,247...113,278,436
JBrowse link
G NCAN neurocan decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of NCAN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAN mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:19,211,958...19,252,233
Ensembl chr19:19,211,958...19,252,233
JBrowse link
G NCOA7 nuclear receptor coactivator 7 decreases expression
multiple interactions
EXP mercuric bromide results in decreased expression of NCOA7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:125,781,115...125,932,034
Ensembl chr 6:125,781,161...125,932,034
JBrowse link
G NDFIP2 Nedd4 family interacting protein 2 increases expression
multiple interactions